# EDGAR Filing Document

**Accession Number:** 0001595248
**File Stem:** 0001437749-26-016755
**Filing Date:** 2026-5
**Character Count:** 162657
**Document Hash:** 2abbf4fc3d081022a0541f3147d2368c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-26-016755.hdr.sgml**: 20260513

**ACCESSION NUMBER**: 0001437749-26-016755

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 47

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260513

**DATE AS OF CHANGE**: 20260513

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Genprex, Inc.
- **CENTRAL INDEX KEY:** 0001595248
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 900772347
- **STATE OF INCORPORATION:** TX
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38244
- **FILM NUMBER:** 26974020

**BUSINESS ADDRESS:**
- **STREET 1:** 1601 TRINITY STREET, BLDG. B
- **STREET 2:** SUITE 3.322
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78712
- **BUSINESS PHONE:** 512-537-7997

**MAIL ADDRESS:**
- **STREET 1:** 1601 TRINITY STREET, BLDG. B
- **STREET 2:** SUITE 3.322
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78712

?xml version='1.0' encoding='ASCII'? gnpx20260331_10q.htm

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

**(Mark One)**

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended March 31, 2026**

**or**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from __________________ to ______________**

**Commission File Number: 001-38244**

## GENPREX, INC.
**(Exact name of registrant as specified in its charter)**

---

| | |
|:---|:---|
| <u>**Delaware**</u> | <u>**90-0772347**</u> |
| (State or other jurisdiction of | (I.R.S. Employer |
| incorporation or organization) | Identification No.) |
| <u>**3300 Bee Cave Road, #650-227, Austin, TX**</u> | <u>**78746**</u> |
| (Address of principal executive offices) | (Zip Code) |

---

<u>**(512) 537-7997**</u>

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br> **Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.001 per share | GNPX | The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒&nbsp;&nbsp;&nbsp;&nbsp;

As of May 11, 2026, the registrant had 10,586,402 shares of common stock, par value $0.001 per share, outstanding.

------

[**Table of Contents**](#toc)

**GENPREX, INC.**

**FORM 10-Q **TABLE OF CONTENTS****

---

| | | |
|:---|:---|:---|
|  |  | **Page No.** |
| **PART I** | [**FINANCIAL INFORMATION**](#financialinfo) | [3](#financialinfo) |
| ITEM 1. | [FINANCIAL STATEMENTS](#financialinfo) | [3](#financialinfo) |
|  | [Condensed Consolidated Balance Sheets as of March 31, 2026 (unaudited) and December 31, 2025](#balance) | [3](#balance) |
|  | [Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2026 and 2025 (unaudited)](#operations) | [4](#operations) |
|  | [Condensed Consolidated Statements of Changes in Stockholders' Equity for the Three Months Ended March 31, 2026 and 2025 (unaudited)](#equity) | [5](#equity) |
|  | [Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2026 and 2025 (unaudited)](#cashflow) | [6](#cashflow) |
|  | [Notes to Unaudited Condensed Consolidated Financial Statements](#notes) | [7](#notes) |
| ITEM 2. | [MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS](#MDA) | [21](#MDA) |
| ITEM 3. | [QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK](#Part1_Item3) | [29](#Part1_Item3) |
| ITEM 4. | [CONTROLS AND PROCEDURES](#controls) | [29](#controls) |
| **PART II** | [**OTHER INFORMATION**](#otherinfo) | [30](#otherinfo) |
| ITEM 1. | [LEGAL PROCEEDINGS](#legal) | [30](#legal) |
| ITEM 1A. | [RISK FACTORS](#risk) | [30](#risk) |
| ITEM 2. | [UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS](#unregistered)  | [30](#unregistered) |
| ITEM 3. | [DEFAULTS UPON SENIOR SECURITIES](#Part2_Item3) | [30](#Part2_Item3) |
| ITEM 4. | [MINE SAFETY DISCLOSURES](#Part2_Item4) | [30](#Part2_Item4) |
| ITEM 5. | [OTHER INFORMATION](#item5) | [30](#item5) |
| ITEM 6. | [EXHIBITS](#item6) | [30](#item6) |
| [SIGNATURES](#signatures) | [SIGNATURES](#signatures) | [32](#signatures) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2

------

[**Table of Contents**](#toc)

**PART I - FINANCIAL INFORMATION**

**Item 1. Financial Statements**

**Genprex, Inc.**

**Condensed Consolidated Balance Sheets**

---

| | | |
|:---|:---|:---|
|  | ***March 31,*** | ***December 31,*** |
|  | ***2026*** | ***2025*** |
| **Assets** | ***(unaudited)*** | ***(see Note 2)*** |
| **Current assets:** |  |  |
| Cash and cash equivalents | $18049255 | $7830855 |
| Prepaid expenses and other | 753804 | 525927 |
| Total current assets | 18803059 | 8356782 |
| **Other non-current assets:** |  |  |
| Research and development supplies | 1503207 | 1802228 |
| Total other assets | 1503207 | 1802228 |
| **Total assets** | $20306266 | $10159010 |
| **Liabilities and Stockholders' Equity** |  |  |
| **Current liabilities:** |  |  |
| Accounts payable | $1655028 | $743070 |
| Other current liabilities | 1698468 | 1431564 |
| Total current liabilities | 3353496 | 2174634 |
| **Non-current liabilities:** |  |  |
| &nbsp;&nbsp;&nbsp; Derivative liabilities | 22500 | 22500 |
| &nbsp;&nbsp;&nbsp; Total liabilities | 3375996 | 2197134 |
| Commitments and contingencies (Note 6) |  |  |
| **Stockholders' equity:** |  |  |
| Preferred stock $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at March 31, 2026 and December 31, 2025 |  |  |
| Common stock $0.001 par value: 200,000,000 shares authorized; 9,044,856 and 3,291,488 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 9045 | 3291 |
| Additional paid-in capital | 192411516 | 178986981 |
| Accumulated deficit | (175490291) | (171028396) |
| Total stockholders' equity | 16930270 | 7961876 |
| **Total liabilities and stockholders' equity** | $20306266 | $10159010 |

---

See accompanying notes to the unaudited condensed consolidated financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3

------

[**Table of Contents**](#toc)

**Genprex, Inc.**

**Condensed Consolidated Statements of Operations (unaudited)**

---

| | | |
|:---|:---|:---|
|  | ***Three Months Ended*** | ***Three Months Ended*** |
|  | ***March 31,*** | ***March 31,*** |
|  | ***2026*** | ***2025*** |
| **Operating expenses:** |  |  |
| Depreciation | $— | $— |
| Research and development | 2745945 | 2539993 |
| General and administrative | 1748239 | 1429299 |
| Total operating expenses | 4494184 | 3969292 |
| **Operating loss** | (4494184) | (3969292) |
| Other income | 31748 | 4771 |
| Realized and unrealized gain (loss) | 541 | (80) |
| **Net loss** | $(4461895) | $(3964601) |
| **Net loss per share applicable to common stockholders — basic and diluted** | $(0.64) | $(12.98) |
| **Weighted average number of common shares — basic and diluted** | 6951999 | 305326 |

---

See accompanying notes to the unaudited condensed consolidated financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4

------

[**Table of Contents**](#toc)

**Genprex, Inc.**

**Condensed Consolidated Statements of Changes in Stockholders' Equity (unaudited)**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | ***Common Stock*** | ***Common Stock*** | ***Additional*** | ***Accumulated*** | ***Total*** |
| **Three Months Ended** | ***Shares*** | ***Amount*** | ***Paid-In Capital*** | ***Deficit*** | ***Stockholders' Equity*** |
| Balance at December 31, 2025 | 3291488 | $3291 | $178986981 | $(171028396) | $7961876 |
| Issuance of common stock net of issuance costs | 5714798 | 5715 | 13351142 |  | 13356857 |
| Issuance of common stock for services | 5000 | 5 | 8945 |  | 8950 |
| RSUs conversion to common stock | 33570 | 34 |  |  | 34 |
| Share-based compensation | *—* |  | 64448 |  | 64448 |
| Net loss | *—* |  |  | (4461895) | (4461895) |
| Balance at March 31, 2026 | 9044856 | $9045 | $192411516 | $(175490291) | $16930270 |
| **Three Months Ended** |  |  |  |  |  |
| Balance at December 31, 2024 | 217234 | $217 | $156419381 | $(154799443) | $1620155 |
| Issuance of common stock net of issuance costs | 265574 | 266 | 6027836 |  | 6028102 |
| Issuance of common stock for services | 100 |  | 4510 |  | 4510 |
| RSUs conversion to common stock | 200 |  | 6 |  | 6 |
| Share-based compensation | *—* |  | 179683 |  | 179683 |
| Net loss | *—* |  |  | (3964601) | (3964601) |
| Balance at March 31, 2025 | 483108 | $483 | $162631416 | $(158764044) | $3867855 |

---

See accompanying notes to the unaudited condensed consolidated financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5

------

[**Table of Contents**](#toc)

**Genprex, Inc.**

**Condensed Consolidated Statements of Cash Flows (unaudited)**

---

| | | |
|:---|:---|:---|
|  | ***Three Months Ended March 31,*** | ***Three Months Ended March 31,*** |
|  | ***2026*** | ***2025*** |
| **Cash flows from operating activities:** |  |  |
| Net loss | $(4461895) | $(3964601) |
| Adjustments to reconcile net loss to net cash used in operating activities: |  |  |
| Share-based compensation and issuance of stock for services | 73432 | 184199 |
| Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Prepaid expenses and other | (227877) | (219593) |
| &nbsp;&nbsp;&nbsp;&nbsp; Research and development supplies | 299020 | 200910 |
| Accounts payable | 911959 | 451389 |
| Other current liabilities | 266904 | (813728) |
| Net cash used in operating activities | (3138457) | (4161424) |
| **Cash flows from financing activities:** |  |  |
| Net proceeds from issuances of common stock | 13356857 | 6028102 |
| Net cash provided by financing activities | 13356857 | 6028102 |
| Net increase in cash and cash equivalents | 10218400 | 1866678 |
| **Cash and cash equivalents, beginning of period** | 7830855 | 1601660 |
| **Cash and cash equivalents, end of period** | $18049255 | $3468338 |

---

See accompanying notes to the unaudited condensed consolidated financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6

------

[**Table of Contents**](#toc)

**GENPREX, INC.**

**NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**MARCH 31, 2026**

<u>Note *1* - Description of Business and Basis of Presentation</u>

Unless the context requires otherwise, references to "Genprex," the "Company," "we," "us" or "our" in this Quarterly Report on Form *10*-Q refer to Genprex, Inc. Genprex, incorporated in Delaware in *April 2008,* is a clinical stage gene therapy company pioneering the development of gene-based therapies for large patient populations with unmet medical needs. The Company's oncology platform utilizes its systemic, non-viral ONCOPREX® Delivery System which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. The product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's diabetes technology is designed to work in Type *1* diabetes by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but *may* be distinct enough from beta cells to evade the body's immune system. In Type *2* diabetes, the Company's technology is believed to work by replenishing and rejuvenating exhausted beta cells that make insulin.

*<u>Oncology Platform</u>*

Genprex's lead oncology drug candidate, REQORSA® Gene Therapy (generic name: *quaratusugene ozeplasmid*), previously referred to as GPX-*001,* is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer ("NSCLC") and Small Cell Lung Cancer ("SCLC"). REQORSA has multimodal effects on cancer cells. It has a mechanism of action whereby it decreases cancer cell growth by decreasing glucose metabolism, interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and increases the immune response against cancer cells. In preclinical studies, REQORSA has been shown to be complementary with targeted drugs and immunotherapies. The Company's strategy is to develop REQORSA in combination with currently approved therapies and the Company believes REQORSA's unique attributes position it to provide treatments that improve on these current therapies for patients with NSCLC, SCLC, and possibly other cancers.

The *TUSC2* gene, which is the key component of REQORSA and plays a vital role in cancer suppression and normal cell metabolism, is *one* of a series of genes on the short arm of Chromosome *3* whose therapeutic use is covered by the Company's exclusive worldwide licenses from The University of Texas MD Anderson Cancer Center ("MD Anderson"). The Company believes that its ONCOPREX Delivery System allows for the delivery of a number of cancer-fighting tumor suppressor genes, alone or in combination with other cancer therapies, to combat multiple types of cancer and the Company is in early stages of discovery programs to identify other cancer candidates. Since *not* all patients respond to REQORSA, the Company has been collaborating with researchers at MD Anderson to identify biomarkers that might predict a strong positive response or a lack of response to REQORSA in patients with lung cancer. This preclinical effort has led to the identification of *two* proteins whose expression appears to predict response to REQORSA. This work, titled "*TROP2* and PTEN are biomarkers of primary resistance to *TUSC2* gene therapy in non-small cell lung cancer*" was accepted for a poster presentation at the meeting of the American Association of Cancer Research in *April 2026.* These findings suggest that *TROP2* and PTEN *may* serve as biomarkers to predict *TUSC2* response and guide therapeutic strategies in NSCLC. *TROP2* (trophoblast cell-surface antigen *2*) is a transmembrane glycoprotein that functions as a cell surface receptor. *TROP2* overexpression in adult tissues is a hallmark of many solid tumors, making it a major target for modern cancer therapies. PTEN (phosphatase and tensin homolog) is a tumor suppressor gene that serves as a multi-functional cancer biomarker in a number of cancers, with potential for risk assessment, diagnosis and treatment planning. Validation in specimens from clinical trials will be needed to determine whether these potential biomarkers predict clinical response. In *April 2026,* the Company entered into a new sponsored research agreement with MD Anderson to study biomarkers that *may* predict patient response to REQORSA. The Company is testing patient samples from its clinical trials for selected biomarkers to determine if sensitivities exist among the Company's existing patient population in an effort to guide patient selection and optimize clinical outcomes.

*Acclaim – *1*: The Acclaim-*1* study is a Phase *1/2* clinical trial that has *three* portions - a Phase *1* dose escalation portion, a Phase *2a* expansion portion, and a Phase *2b* randomized portion. The Company currently is enrolling and treating patients in the Phase *2a* expansion portion of its Phase *1/2* Acclaim-*1* clinical trial. The Acclaim-*1* trial uses a combination of REQORSA and AstraZeneca's Tagrisso® (*osimertinib*) in patients with late-stage NSCLC who have activating epidermal growth factor receptor ("EGFR") mutations and disease progression on treatment with Tagrisso or Tagrisso-containing regimens. Following the *May 2023* completion of the Phase *1* dose escalation portion of the study, the Acclaim-*1* Safety Review Committee ("Acclaim-*1* SRC") approved advancement from the Phase *1* dose escalation portion to the Phase *2a* expansion portion of the study. Based on a review of safety data which showed *no* dose limiting toxicities ("DLTs"), the Acclaim-*1* SRC determined the recommended Phase *2* dose (*"RP2D"*) of REQORSA to be *0.12* mg/kg administered every *21* days. This was the highest dose level delivered in the Phase *1* portion of the study and is twice the highest dose level delivered in the Company's prior clinical trial combining REQORSA with Tarceva® (*erlotinib*) for the treatment of late-stage lung cancer. There were *three* patients out of the *twelve* originally enrolled in the Phase *1* dose escalation portion of the study who had prolonged progression-free survival ("PFS"). One patient attained a partial remission after the *second* course of REQORSA and Tagrisso and has maintained this response through *64* courses of treatment (approximately *48* months) and this patient continues to receive REQORSA and Tagrisso treatment to date. A *second* patient had stable disease without disease progression through *32* courses of treatment (approximately *24* months), but then had disease progression and REQORSA treatment was stopped. A *third* patient had stable disease without disease progression through *14* courses of treatment (approximately *10* months) before disease progression and is *no* longer receiving treatment. The results of the Phase *1* dose escalation portion of the study were published in *Clinical Lung Cancer*, a peer-reviewed journal covering various aspects of clinical and translational research of lung cancer, in *January 2026.* Genprex opened the Phase *2a* expansion portion of the study and enrolled and dosed the *first* patient in *January 2024.* The Phase *2a* expansion portion of the trial is expected to enroll approximately *33* patients, all of whom had disease progression on Tagrisso or Tagrisso-containing regimens. There will be an interim analysis following the treatment of *19* patients in the Phase *2a* portion of the Acclaim-*1* study. The Company expects to complete the enrollment of the *first 19* patients for interim analysis in the Phase *2a* expansion portion of the study in the *first* half of *2026* and expects the interim analysis in the *second* half of *2026.*

The Food and Drug Administration ("FDA") has granted Fast Track Designation for the Acclaim-*1* treatment combination of REQORSA and Tagrisso in NSCLC patients who have progressed on Tagrisso treatment.

The Phase *2a* expansion portion of the Acclaim-*1* study provides the Company the advantage of early insight into drug effectiveness in defined and distinct patient populations at the maximum tolerated dose or *RP2D* in order to better evaluate efficacy and increase the likelihood of a successful randomized Phase *2* trial which will follow the expansion portion of the study.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *7*

------

**GENPREX, INC.**

**NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

 ***MARCH 31, 2026***

*Acclaim – *3*: The Acclaim-*3* study has *two* portions - a Phase *1* dose escalation portion and a Phase *2* expansion portion. The Company is currently enrolling and treating patients in the Phase *2* expansion portion of its Phase *1/2* Acclaim-*3* clinical trial. The Acclaim-*3* clinical trial uses a combination of REQORSA and Genentech, Inc.'s Tecentriq® (*atezolizumab*) as maintenance therapy for patients with extensive stage small cell lung cancer ("ES-SCLC") who did *not* develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. Patients are treated with REQORSA and Tecentriq until disease progression or unacceptable toxicity is experienced. In *December 2024,* the Company announced that it had completed the Phase *1* dose escalation portion of the Acclaim-*3* clinical trial. Based on full safety data, which showed *no* DLTs, the Acclaim-*3* Safety Review Committee ("Acclaim-*3* SRC") determined that the *RP2D* of REQORSA will be *0.12* mg/kg administered every *21* days, which was the highest dose level delivered in the Phase *1* portion of the trial, and approved the opening of the Phase *2* expansion portion of the trial. Although decreases in tumor size are *not* expected during maintenance therapy with atezolizumab alone, there were *two* patients out of the *six* enrolled in the Phase *1* dose escalation portion of the study who had marked decreases in measurable disease. The Company previously reported that the *first* patient treated in the Phase *1* dose escalation portion of the Acclaim-*3* trial had a partial remission, which is defined as at least a *thirty* percent (*30%*) decrease in tumor size, from prior to the start of maintenance therapy to the time of the CT scan performed after *two* cycles of maintenance therapy. A CT scan performed after *four* cycles of maintenance therapy (*three* months), confirmed that the patient still had a *30%* decrease in tumor size in measurable lesions; however, *one* lesion *not* previously measurable had grown in size, thus leading to a conclusion of disease progression at that time. Another patient in the Phase *1* dose escalation portion of the Acclaim-*3* trial had a *twenty-three* percent (*23%*) decrease in tumor size from prior to the start of maintenance therapy to the time of the CT scan performed after *two* cycles of maintenance therapy. This patient received *seven* cycles of study therapy before progressing after *4.2* months. In addition, *one* patient in the Phase *1* dose escalation portion of the study achieved an unconfirmed partial remission after *24* cycles of therapy and continues to receive study treatment in the trial after more than *19* months. The Company anticipates that the Phase *2* expansion portion will enroll approximately *50* patients at approximately *10* to *15* U.S sites. Patients will be treated with REQORSA and Tecentriq until disease progression or unacceptable toxicity is experienced. The primary endpoint of the Phase *2* portion is to determine the *18*-week progression-free survival rate from the start of maintenance therapy with REQORSA and Tecentriq in patients with ES-SCLC. Patients will also be followed for survival. A Phase *2* futility analysis will be performed after the *25th* patient enrolled and treated reaches *18* weeks of follow up. The Company expects to complete enrollment of the *first 25* patients for interim analysis in the Phase *2* expansion portion of the study in the *first* half of *2026* and expects the interim analysis in the *second* half of *2026.*

The Acclaim-*3* clinical trial has received FDA Fast Track Designation for this patient population and Acclaim-*3* has also received an FDA Orphan Drug Designation.

*<u>Diabetes Gene Therapy</u>*

In diabetes, Genprex has exclusively licensed from the University of Pittsburgh of the Commonwealth System of Higher Education ("University of Pittsburgh" or "UP") multiple technologies relating to the development of a gene therapy product for each of Type *1* and Type *2* diabetes. The same novel approach is used in each of Type *1* and Type *2* diabetes whereby an adeno-associated virus ("AAV") vector containing the *Pdx1* and MafA genes is administered directly into the pancreatic duct. In humans, this can be done with a routine endoscopy procedure. The Company's diabetes product candidates are currently being evaluated and optimized in preclinical studies at the University of Pittsburgh. GPX-*002* is being developed for the treatment of both Type *1* diabetes and Type *2* diabetes. GPX-*002* for Type *1* diabetes is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but *may* be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-*002* for Type *2* diabetes, where autoimmunity is *not* at play, is believed to work by replenishing and rejuvenating exhausted beta cells that make insulin. The Company is currently working with the University of Pittsburgh on species analyses for the animal models as well as other regulatory and clinical strategic planning, including the initiation of research in Type *2* diabetes animal models. In *December 2025,* the Company also executed on its strategic goal to submit a meeting request to the FDA by the end of the year to discuss the necessary Investigational New Drug ("IND")-enabling preclinical studies, an important step before potentially initiating clinical trials in humans. See the discussion captioned "Recent Developments – Diabetes Gene Therapy Updates" in "Part I, Item *2.* Management's Discussion and Analysis of Financial Condition and Results of Operations" appearing in this Quarterly Report on Form *10*-Q below for more information on the Company's meeting with the FDA which occurred in *February 2026.* In *May 2025,* following the completion of the Company's *August 2022* sponsored research agreement with UP, the Company entered into a new sponsored research agreement with UP to study Type *1* diabetes and Type *2* diabetes in animal models. The new sponsored research agreement also includes a revised research plan to encompass the Company's most recent technologies to which Genprex originally acquired exclusive rights from UP in *July 2023* as amended and restated in the comprehensive New UP License Agreement in *February 2025 (*as defined and described below). These include a MafB promoter to drive expression of the *Pdx1* and MafA transcription factors that can potentially be used for both Type *1* and Type *2* diabetes. See also "Note *6* – Commitments and Contingencies".

On *February 17, 2025,* the Company and the University of Pittsburgh entered into an amended and restated Exclusive License Agreement (the "New UP License Agreement"), which updated and consolidated into a single agreement the Company's prior license agreements with UP. Pursuant to the New UP License Agreement, UP granted to the Company a worldwide, exclusive license for certain patents and related technology, collectively referred to as the "Licensed Technology," and a worldwide, non-exclusive license to use certain related know-how. The Licensed Technology covered by the New UP License Agreement is based on the same general gene therapy approach as covered under the Company's prior license agreements with UP (less the previously-licensed macrophage technology), whereby an adeno-associated virus vector containing the *Pdx1* and MafA genes is administered directly into the pancreatic duct. More specifically, the Licensed Technology covered by the New UP License Agreement is related to a gene therapy for both Type *1* diabetes and Type *2* diabetes using the genes of the *Pdx1* and MafA transcription factors controlled by insulin, glucagon and MafB promoters.

In *February 2023,* the Company's research collaborators at UP presented preclinical data in a non-human primate ("NHP") model of Type *1* diabetes highlighting the therapeutic potential of GPX-*002* at the *16th* International Conference on Advanced Technologies & Treatments for Diabetes ("ATTD *2023"*) in Berlin, Germany. The statistically significant study results showed the treated animals had decreased insulin requirements, increased c-peptide levels, and improved glucose tolerance compared to baseline. In *April 2023,* the Company hosted a Key Opinion Leader virtual event entitled "Novel Gene Therapy to Treat Type *1* Diabetes," which discussed preclinical data reported at ATTD *2023* supporting gene therapy to treat Type *1* diabetes. In *June 2025,* the Company's collaboration partners had *two* presentations at the *2025* American Diabetes Association ("ADA") *85th* Scientific Sessions. The Company's research collaborators from UP were invited to give an oral presentation highlighting their work in NHP models of Type *1* diabetes. In addition, the Company's contract development and manufacturing organization collaborators presented a poster on a non-viral lipid nanoparticle delivery system that would allow a patient to receive multiple treatments.

*<u>Formation of Wholly Owned Subsidiary</u>*

On *February 18, 2025,* Genprex announced the formation of a wholly-owned subsidiary, Convergen Biotech, Inc. ("Convergen") in connection with a potential separation of the diabetes clinical development program. If, and when, a potential separation is completed, the Company would plan to transfer the diabetes program into Convergen in an effort to focus development and commercialization efforts separately from the Company's oncology program and other oncology pipeline assets.

<u>*Capital Requirements, Liquidity and Going Concern Considerations*</u>

The Company's unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP") applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, the Company has sustained substantial losses from operations since inception and has *no* current source of revenue. In addition, the Company has used, rather than provided, cash in its operations. Genprex expects to continue to incur significant expenditures to further clinical trials for the commercial development of its patents.

The Company recognizes that it must obtain additional capital resources to successfully commercialize its product candidates. To date, Genprex has received funding in the form of equity and debt, and the Company plans to seek additional funding in the future. However, *no* assurances can be given that it will be successful in raising additional capital. If the Company is *not* able to timely and successfully raise additional capital, the timing of its clinical trials, financial condition and results of operations *may* be materially and adversely affected. These unaudited condensed consolidated financial statements do *not* include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities.

Genprex believes that its current cash and cash equivalents will be sufficient to fund expenditure requirements for its necessary operations and expected clinical trial activities into the *second* half of *2027.* Genprex has based these estimates, however, on assumptions that *may* prove to be wrong, and could spend available financial resources much faster than it currently expects. The Company will need to raise additional funds to continue funding its development and operations. The Company plans to secure such additional funding and is evaluating various strategies to obtain additional financing, although the Company can give *no* assurance that its plans or strategies will be effectively implemented in such a way that they will sufficiently alleviate or mitigate the conditions and events noted above.

As a result of its recurring losses from operations and the need for additional financing to fund its operating and capital requirements, there is uncertainty regarding the Company's ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt as to the Company's ability to continue as a going concern. These unaudited condensed consolidated financial statements do *not* include any adjustments that might be necessary if Genprex is unable to continue as a going concern.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *8*

------

[**Table of Contents**](#toc)

**GENPREX, INC.**

**NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

 ***MARCH 31, 2026***

<u>Note *2* - Summary of Significant Accounting Policies</u>

Genprex's unaudited condensed consolidated financial statements have been prepared in accordance with US GAAP and the requirements of the United States Securities and Exchange Commission (the "SEC") for interim reporting. As permitted under those rules, certain footnotes or other financial information that is normally required by US GAAP can be condensed or omitted. Accordingly, they do *not* include all of the information and footnotes normally included in financial statements prepared in conformity with US GAAP. The *December 31, 2025* balance sheet was derived from the *December 31, 2025* audited financial statements. Genprex's unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company's *2025* Annual Report on Form *10*-K, filed with the SEC on *March 30, 2026 (*the "Form *10*-K").

The accompanying condensed consolidated financial statements are unaudited and include all adjustments (consisting of normal recurring adjustments) that management considers necessary for a fair presentation of Genprex's condensed consolidated financial position and results of operations for the interim periods presented. The results of operations for the interim periods are *not* necessarily indicative of the results that *may* be expected for any other interim period or for the entire year.

A summary of Genprex's significant accounting policies consistently applied in the preparation of the accompanying unaudited condensed consolidated financial statements follows.

*<u>Principles of Consolidation</u>*

The accompanying unaudited condensed consolidated financial statements, which include the accounts of the Company and its wholly-owned subsidiary, Convergen Biotech, Inc., have been prepared in accordance with US GAAP for interim financial information and with the instructions to Form *10*-Q and Article *10* of Regulation S-*X.* All significant intercompany balances and transactions are eliminated in consolidation. As of *March 31, 2026*, Convergen Biotech, Inc. has yet to initiate operating activity.

<u>*Reverse Stock Split*</u>

On *October 21, 2025,* Genprex completed a *1*-for-50 reverse stock split (*"2025* Reverse Split") of its issued and outstanding shares of common stock. The *2025* Reverse Split did *not* change the number of authorized shares of common stock or par value of the common stock. All references in these unaudited condensed consolidated financial statements to shares, share prices, exercise prices, and other per share information in all periods have been adjusted, on a retroactive basis, to reflect the *2025* Reverse Split (see "Note *4* – Equity – *2025* Reverse Stock Split").

<u>*Use of Estimates*</u>

The preparation of Genprex's unaudited condensed consolidated financial statements in conformity with US GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

<u>*Cash and Cash Equivalents*</u>

Genprex considers all highly liquid short-term investments with an initial maturity of *three* months or less to be cash equivalents. Any amounts of cash in financial institutions which exceed Federal Deposit Insurance Corporation ("FDIC") insured limits expose the Company to cash concentration risk. The Company has cash in a money market account and had $17,799,219 and $7,580,820 in excess of FDIC insured limits of *$250,000* at *March 31, 2026* and *December 31, 2025*, respectively. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company's financial condition, results of operations, and cash flows.

<u>*Net Loss Per Share*</u>

Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock, which includes common stock equivalents consisting of (i) 1,325,388 unexercised options granted by the Company's board of directors and unexercised warrants to purchase shares of common stock, and (ii) 85,179 unvested restricted stock units granted by the Company's board of directors representing the right upon vesting to receive shares of common stock, in each case as of *March 31, 2026*.

*<u>Segments</u>*

Operating segments are defined as components of an entity for which separate discrete financial information is made available and that is regularly evaluated by the chief operating decision maker ("CODM") in making decisions regarding resource allocation and assessing performance. The Company's CODM is its Chief Executive Officer and the Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company is focused on pioneering the discovery and development of gene therapies for use in patient populations with unmet medical needs. See "Note *7* – Segment Reporting" for additional disclosures related to segment reporting.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *9*

------

[**Table of Contents**](#toc)

**GENPREX, INC.**

**NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

 ***MARCH 31, 2026***

<u>*Fair Value of Financial Instruments*</u>

The carrying amounts reported in the condensed consolidated balance sheets for cash, money-market savings account, accounts receivable, and accounts payable approximate fair value because of the immediate or short-term maturity of these financial instruments.

Accounting Standards Codification ("ASC") *820, Fair Value Measurements and Disclosures*, defines fair value, provides a consistent framework for measuring fair value under US GAAP and expands fair value financial statement disclosure requirements. ASC *820's* valuation techniques are based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. ASC *820* classifies these inputs into the following hierarchy:

Level *1:* Quoted prices for identical instruments in active markets.

Level *2:* Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are *not* active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.

Level *3:* Instruments with primarily unobservable value drivers.

<u>*Property and Equipment*</u>

Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from three to five years. Routine maintenance and repairs are charged to expense as incurred and major renovations or improvements are capitalized.

<u>*Research and Development Costs*</u>

Research and development expenditures consist of costs incurred to conduct research, develop engineering materials for further study, and develop clinical strategies for current and future programs associated with the Company's preclinical and Phase *1/2* clinical trials. These expenditures are expensed in the period incurred and include payments to collaborative research partners, manufacturing partners and consultants, and clinical strategy partners, wages and associated employee benefits, facilities, and overhead costs.

Materials acquired to be used in clinical research, that have an alternative future use, are capitalized when the materials are acquired, and included in research and development supplies. These supplies are recognized as expense as they are consumed through use for testing or clinical activities, or have spoiled. The costs of materials that were acquired for a particular research and development activity and have *no* alternative future use are expensed in the period acquired.

Research and development supplies purchased, valued at cost, and capitalized for future use were $1,503,207 and $1,802,228 at *March 31, 2026* and *December 31, 2025*, respectively.

<u>*Intellectual Property*</u>

Intellectual property consists of legal and related costs associated with patents, trademarks, and other proprietary technology and rights developed, acquired, or licensed by Genprex. Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. These patent-related legal costs are reported as a component of general and administrative expenses.

<u>*Accounting for Stock-Based Compensation*</u>

Genprex uses the fair value-based method of accounting for stock-based compensation for options granted to employees, independent consultants and contractors. The Company measures options granted at fair value determined as of the grant date and recognizes the expense over the periods in which the options vest or are expected to vest and related services are rendered based on the terms and conditions of the award. Generally, where the award only has a service condition, the requisite service period is the same as the vesting period.

<u>*Long-Lived Assets*</u>

Genprex reviews long-lived assets and certain identifiable intangibles held and used for possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset *may not* be recoverable. In evaluating the fair value and future benefits of its intangible assets, the Company performs an analysis of the anticipated undiscounted future net cash flow of the individual assets over the remaining amortization period. The Company recognizes an impairment loss if the carrying value of the asset exceeds the discounted expected future cash flows. During the *three* months ended *March 31, 2026*, there were no deemed impairments of the Company's long-lived assets.

<u>*Derivative Liability*</u>

The Company evaluates all features contained in financing agreements to determine if there are any embedded derivatives that require separate accounting from the underlying agreement under ASC *815, Derivatives and Hedging*. An embedded derivative that requires separation is accounted for as a separate asset or liability from the host agreement. The derivative asset or liability is accounted for at fair value, with changes in fair value recognized in the condensed consolidated statements of operations within the other financing costs line item. The Company determined that certain features under the Equity Line of Credit (see "Note *4* – Equity – Equity Line of Credit") qualified as an embedded derivative. The derivative liability is accounted for separately from the Equity Line of Credit Purchase Agreement and is accounted for at fair value. $22,500 has been recorded on the accompanying condensed consolidated balance sheets as of *March 31, 2026* and *December 31, 2025*, related to this derivative liability.

<u>*Recent Accounting Developments*</u>

Accounting pronouncements issued but *not* effective until after *March 31, 2026*, are *not* expected to have a significant effect on the Company's consolidated financial condition, results of operations, or cash flows.

In *December 2023,* the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") *2023*-*09, Income Taxes (Topic *740*): Improvements to Income Tax Disclosures*, which modifies the rules on income tax disclosures to require disaggregated information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. The guidance is effective for annual periods beginning after *December 15, 2024,* with early adoption permitted. The Company adopted the standard effective *January 1, 2025* and there was *no* material impact to the Company's consolidated financial statements.

In *December 2025,* the FASB issued ASU *2025*-*11, Interim Reporting (Topic *270*): Narrow-Scope Improvements*, which is intended to clarify the applicability of interim reporting guidance, the types of interim reporting and the form and content of interim US GAAP financial statements. ASU *2025*-*11* will be effective for the Company's fiscal year beginning on *September 1, 2028* and the Company is currently evaluating the impact it *may* have on its interim condensed consolidated financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *10*

------

[**Table of Contents**](#toc)

**GENPREX, INC.**

**NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

 ***MARCH 31, 2026***

<u>Note *3* - Intellectual Property</u>

As of *March 31, 2026*, Genprex owned or had exclusive license agreements on 15 granted patents and 28 pending patent applications worldwide for technologies developed in-house or by researchers at the National Cancer Institute, New York University, The University of Texas MD Anderson Cancer Center, the University of Texas Southwestern Medical Center, the University of Texas Health Sciences Center at Houston, the University of Michigan, and the University of Pittsburgh. These patents comprise various therapeutic, diagnostic, technical and processing claims and costs are expensed as incurred. These license rights will be amortized on a straight-line basis over the estimated period of useful lives of the underlying patents or the license agreements.

*University of Pittsburgh*

On *February 17, 2025,* Genprex and the University of Pittsburgh entered into the New UP License Agreement to update and consolidate, into a single agreement, prior license agreements and licensed technologies covered by the Company's prior agreements with the University of Pittsburgh related to a gene therapy for both Type *1* diabetes and Type *2* diabetes using the genes of the *Pdx1* and MafA transcription factors controlled by insulin, glucagon and MafB promoters. As of *February 17, 2025,* the New UP License Agreement effectuates the termination of, and amends, restates, replaces and supersedes in their entirety, the prior license agreements between Genprex and the University of Pittsburgh which were effective as of *February 10, 2020 (*as amended *August 17, 2022* and *November 3, 2022), December 29, 2022* and *July 14, 2023.* Genprex also terminated, effective *February 17, 2025,* a prior agreement with UP related to a license for macrophage technology dated *November 22, 2022.*

*The University of Texas MD Anderson Cancer Center*

On *May 4, 2020,* Genprex entered into an exclusive worldwide license agreement with The Board of Regents of the University of Texas System on behalf of MD Anderson relating to a portfolio of patent applications and related technology for the treatment of cancer using the Company's lead drug candidate and immunotherapies. See "Note *6* - Commitments and Contingencies - Commitments - MD Anderson Cancer Center" for information on additional agreements involving MD Anderson licensed rights and technologies.

*University of Michigan*

On *November 11, 2024,* Genprex and the Regents of the University of Michigan ("UM" or the "University of Michigan") entered into a Patent License Agreement ("UM License Agreement"), which granted Genprex a worldwide, exclusive license to the University of Michigan's patent rights in a co-owned patent application relating to the use of REQORSA in combination with ALK-inhibitors for the treatment of ALK-*EML4* positive translocated lung cancer.

*New York University* 

On *April 25, 2025,* the Company and New York University ("NYU") entered into a License Agreement (the "NYU License Agreement"), which granted Genprex exclusive patent and commercial rights worldwide relating to Genprex's lead drug candidate REQORSA for the potential treatment of mesothelioma.

*University of Texas Health Sciences Center at Houston*

On *May 2, 2025,* the Company and the Board of Regents of The University of Texas System on behalf of The University of Texas Health Sciences Center at Houston ("UTHealth Houston" or "UTH") entered into a Patent and Technology License Agreement (the "UTH License Agreement"), which granted Genprex exclusive patent and commercial rights worldwide relating to Genprex's lead drug candidate REQORSA for the potential treatment of glioblastoma.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *11*

------

[**Table of Contents**](#toc)

**GENPREX, INC.**

**NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

 ***MARCH 31, 2026***

<u>Note *4* - Equity</u>

<u>*2025* Reverse Stock Split*</u>

On *October 21, 2025,* Genprex completed a *1*-for-50 Reverse Split of its issued and outstanding shares of common stock. The *2025* Reverse Split did *not* change the number of authorized shares of common stock or the par value. All references in these unaudited condensed consolidated financial statements to shares, share prices, exercise prices, and other per share information in all periods have been adjusted, on a retroactive basis, to reflect the *2025* Reverse Split.

<u>*Registered Direct Offerings*</u>

On *October 24, 2025,* Genprex completed a registered direct offering priced at-the-market under Nasdaq rules (the *"October 2025* Registered Direct Offering I"), pursuant to which the Company issued an aggregate of 243,622 shares of common stock at a purchase price of $11.21 per share. In a concurrent private placement (the *"October 2025* Private Placement I", and together with the *October 2025* Registered Direct Offering I, the *"October 2025* Financing I"), the Company issued warrants (the *"October 2025* Private Warrants I") exercisable for up to an aggregate of 487,244 shares of common stock (the *"October 2025* Private Warrant Shares I") at an exercise price of $11.00 per share. The *October 2025* Private Warrants I are exercisable immediately upon issuance and will expire on *December 12, 2027.* Also, the Company agreed to issue to H.C. Wainwright & Co., LLC (the "Placement Agent") or its designees warrants to purchase up to an aggregate of 14,617 shares of common stock. The warrants issued to the Placement Agent or its designees have substantially the same terms as the *October 2025* Private Warrants I except that the warrants issued to the Placement Agent or its designees have an exercise price of $14.0125 per share. The net proceeds of the *October 2025* Financing I, after deducting the placement agent's fees and expenses and other estimated *October 2025* Registered Direct Offering I expenses payable by the Company and excluding the net proceeds, if any, from the exercise of the *October 2025* Private Warrants I, were approximately $2.5 million. Additionally, if the holders of *October 2025* Private Warrants I exercise such warrants in full, the Company would receive additional gross proceeds of approximately $5.4 million.

On *October 29, 2025,* Genprex completed a registered direct offering priced at-the-market under Nasdaq rules (the *"October 2025* Registered Direct Offering II"), pursuant to which the Company issued an aggregate of 377,780 shares of common stock at a purchase price of $9.00 per share. In a concurrent private placement (the *"October 2025* Private Placement II", and together with the *October 2025* Registered Direct Offering II, the *"October 2025* Financing II"), the Company issued warrants (the *"October 2025* Private Warrants II") exercisable for up to an aggregate of 755,560 shares of common stock (the *"October 2025* Private Warrant Shares II") at an exercise price of $8.75 per share. The *October 2025* Private Warrants II are exercisable immediately upon issuance and will expire on *December 12, 2027.* Also, the Company agreed to issue to H.C. Wainwright & Co., LLC (the "Placement Agent") or its designees warrants to purchase up to an aggregate of 22,667 shares of common stock. The warrants issued to the Placement Agent or its designees have substantially the same terms as the *October 2025* Private Warrants II except that the warrants issued to the Placement Agent or its designees have an exercise price of $11.25 per share. In addition, in connection with any future exercise of the *October 2025* Private Warrants II, the Company has agreed to (A) pay the Placement Agent (i) a cash fee equal to 7.0% of the aggregate gross exercise price paid in cash with respect to the exercise of such warrants and (ii) a management fee equal to 1.0% of the aggregate gross exercise price paid in cash with respect to the exercise of such warrants and (B) issue to Placement Agent or its designees additional placement agent warrants to purchase that number of shares equal to 6.0% of the aggregate number of shares of common stock underlying such *October 2025* Private Warrants II that have been exercised. The net proceeds of the *October 2025* Financing II, after deducting the placement agent's fees and expenses and other estimated *October 2025* Registered Direct Offering II expenses payable by the Company and excluding the net proceeds, if any, from the exercise of the *October 2025* Private Warrants II, were approximately $3.1 million. Additionally, if the holders of *October 2025* Private Warrants II exercise such warrants in full, the Company would receive additional net proceeds of approximately $6.1 million.

*<u>At-The-Market Offering</u>*

On *December 13, 2023,* Genprex entered into an At The Market ("ATM") Offering Agreement (the "Sales Agreement") with H.C. Wainwright & Co., LLC, serving as agent (the "Agent") with respect to an at-the-market offering program (the *"2023* ATM Facility") under which the Company *may* offer and sell through the Agent, from time to time at its sole discretion, up to such number or dollar amount of shares of its common stock (the "Shares") as registered on the prospectus supplement covering the *2023* ATM Facility offering, as *may* be amended or supplemented from time to time. Any Shares offered and sold pursuant to the Sales Agreement will be issued pursuant to the Company's currently effective shelf Registration Statement on Form S-*3* (File *No. 333*-*271386*) filed with the SEC on *April 21, 2023,* which was declared effective on *June 9, 2023,* as *may* be amended or supplemented from time to time, or pursuant to any new or successor shelf Registration Statement of the Company. The Company has agreed to pay the Agent a commission equal to *three* percent (3%) of the gross sales proceeds of any Shares sold through the Agent under the Sales Agreement, and also has provided the Agent with customary indemnification and contribution rights. During the *three* months ended *March 31, 2025*, the Company sold 265,574 Shares of common stock for aggregate net proceeds of approximately $6.03 million under the *2023* ATM Facility. During the *three* months ended *March 31, 2026*, the Company sold 5,714,798 Shares of common stock for aggregate net proceeds of approximately $13.36 million under the *2023* ATM Facility.

See "Note *8* – Subsequent Events – *2023* ATM Facility" for a description of the Company's usage of the *2023* ATM Facility after *March 31, 2026* resulting in net proceeds of approximately $1.90 million.

*<u>Equity Line of Credit</u>*

On *June 11, 2025,* Genprex entered into an equity line of credit ("ELOC") purchase agreement (the "Purchase Agreement") with Lincoln Park Capital Fund, LLC ("Lincoln Park"), pursuant to which Lincoln Park committed to purchase up to $12.5 million in shares of the Company's common stock (subject to certain conditions and limitations contained in the Purchase Agreement) from time to time at the Company's sole discretion over the *24*-month term of the Purchase Agreement (the *"2025* ELOC Facility"). Sales of shares of common stock to Lincoln Park under the Purchase Agreement will depend on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, the trading price of the common stock and the Company's determination as to the appropriate sources of funding for its operations. Due to certain pricing and settlement provisions, the Purchase Agreement qualifies as a standby purchase equity agreement and includes an embedded put option and an embedded forward contract. Genprex will account for the Purchase Agreement as a derivative measured at fair value, with changes in fair value recognized in the condensed consolidated statement of operations. The put option derivative liability is accounted for on a fair value basis under the provisions of ASC *815, Derivatives and Hedging*. The derivative associated with the Purchase Agreement was deemed de minimus at inception until the Company obtained stockholder approval to issue shares of common stock to Lincoln Park under the Purchase Agreement in excess of the Exchange Cap (as defined in the Purchase Agreement). The fair value of the ELOC Purchase Agreement contemplated future purchase decisions based on economic considerations and relevant stock issuance rules and limitations and has been determined using a Monte Carlo simulation. The fair value of the ELOC derivative liability was $22,500 at *March 31, 2026* and *December 31, 2025*

The following table provides the carrying value and fair value of the ELOC derivative liability of the Company measured at fair value on a recurring basis as of *March 31, 2026*:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  | ***Fair Value Measurement at March 31, 2026*** | ***Fair Value Measurement at March 31, 2026*** | ***Fair Value Measurement at March 31, 2026*** |
|  | ***Carrying Value*** | ***Level 1*** | ***Level 2*** | ***Level 3*** |
| Liabilities: |  |  |  |  |
| Derivative liability | $22500 |  |  | $22500 |
| Totals liabilities measured and recorded at fair value | $22500 | $— | $— | $22500 |
|  |  | ***Fair Value Measurement at December 31, 2025*** | ***Fair Value Measurement at December 31, 2025*** | ***Fair Value Measurement at December 31, 2025*** |
|  | ***Carrying Value*** | ***Level 1*** | ***Level 2*** | ***Level 3*** |
| Liabilities: |  |  |  |  |
| Derivative liability | $22500 |  |  | $22500 |
| Totals liabilities measured and recorded at fair value | $22500 | $— | $— | $22500 |

---

The following table provides quantitative information regarding fair value measurements inputs used with respect to the ELOC derivative liability, as of their respective measurement dates:

---

| | | |
|:---|:---|:---|
|  | ***March 31, 2026*** | ***December 31, 2025*** |
| Closing stock price: | $0.17 | $0.17 |
| Volatility: | 180.0% | 180.0% |
| Expected term (in years): | 1.70 | 1.70 |
| Risk-free rate: | 3.6% | 3.6% |

---

The Company expenses the difference between the discounted purchase price of the settled forward and the fair value of the shares on the date of settlement as a non-cash financing cost. There were no sales of common stock pursuant to the ELOC during each of the *three* months ended *March 31, 2025* and *March 31, 2026*.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *12*

------

**GENPREX, INC.**

**NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

 ***MARCH 31, 2026***

<u>*Stock Issuances*</u>

During the *three* months ended *March 31, 2026*, the Company issued (i) 5,000 shares of common stock for services provided to the Company valued at $8,950 to the Chairman of its Scientific Advisory Board, (ii) 33,570 shares of common stock upon the vesting of restricted stock units ("RSUs") valued at $67,015 to Company executives, employees, and non-employee service providers, and (iii) 5,714,798 shares of common stock sold for aggregate net proceeds of approximately $13.36 million under the *2023* ATM Facility.

During the *three* months ended *March 31, 2025*, Genprex issued (i) 100 shares of common stock for services provided to the Company valued at $4,505 to the Chairman of its Scientific Advisory Board, (ii) 200 shares of common stock upon the vesting of restricted stock units ("RSUs") valued at $3,853 to Company executives, employees, and non-employee service providers, and (iii) 265,574 shares of common stock sold for aggregate net proceeds of approximately $6.03 million under the Company's *2023* ATM Facility.

<u>*Preferred Stock*</u>

Genprex is authorized to issue 10,000,000 shares of preferred stock with a par value of $0.001 per share, none of which are outstanding as of *March 31, 2026* and *December 31, 2025*.

<u>*Common Stock*</u>

Genprex is authorized to issue 200,000,000 shares of common stock with a par value of $0.001 per share, all of which are voting common stock. There were 9,044,856 and 3,291,488 shares of its common stock outstanding as of *March 31, 2026* and *December 31, 2025*, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *13*

------

**GENPREX, INC.**

**NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

 ***MARCH 31, 2026***

<u>*Common Stock Purchase Warrants*</u>

Common stock purchase warrant activity for the *three* months ended *March 31, 2026* and *2025*, respectively, is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***2026*** | ***2026*** | ***2025*** | ***2025*** |
|  | ***Number of*** | ***Weighted Average*** | ***Number of*** | ***Weighted Average*** |
|  | ***Warrants*** | ***Exercise Price*** | ***Warrants*** | ***Exercise Price*** |
| Outstanding at January 1, | 1319696 | $24.40 | 39633 | $503.75 |
| Warrants cancelled or expired | 13 | 14440.00 |  |  |
| Outstanding at March 31, | 1319683 | $24.26 | 39633 | $503.75 |

---

During the *three* months ended *March 31, 2026*, the Company canceled warrants to purchase up to 13 shares of common stock at a weighted average exercise price of $14,440.00. The Company did not record any share-based compensation related to warrants during the *three* months ended *March 31, 2026*. The Company expects to record $300,000 of share-based compensation based on performance-based vesting in the future with respect to its warrants outstanding as of *March 31, 2026*.

The Company did not issue or cancel any warrants during the *three* months ended *March 31, 2025*. The Company did not record any share-based compensation related to warrants during the *three* months ended *March 31, 2025*.

As of *March 31, 2026*, the Company had outstanding warrants to purchase 1,319,683 shares of common stock at a weighted average exercise price of $24.26 that have been issued to various consultants, investors, and placement agents. The warrants are fully vested, are exercisable for a period of up to five years from the date of issuance, enable the holders to purchase shares of the Company's common stock at exercise prices ranging from $8.75 to $10,571.00 per share and have per-share fair values ranging from $2.42 to $6,960.00, based on Black-Scholes-Merton pricing models. No warrants were issued in each of the *three* months ended *March 31, 2026*, or *March 31, 2025*.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *14*

------

[**Table of Contents**](#toc)

**GENPREX, INC.**

**NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

 ***MARCH 31, 2026***

<u>*2018* Equity Incentive Plan*</u>

The Company's board of directors and stockholders have approved and adopted the Genprex *2018* Equity Incentive Plan (*"2018* Plan"), which initially became effective on the completion of the Company's IPO on *April 3, 2018.* The *2018* Plan provides for the grant of incentive stock options that are intended to qualify under Section *422* of the Internal Revenue Code of *1986,* as amended ("ISOs"), nonstatutory stock options, stock appreciation rights, restricted stock awards, RSU awards, performance-based stock awards and performance-based cash awards. ISOs *may* be granted only to employees. All other awards *may* be granted to employees, including officers, and to the Company's non-employee directors and consultants.

A total of 2,080 shares of common stock were initially available under the *2018* Plan, plus a number of shares of common stock (*not* to exceed 1,314 shares) subject to outstanding awards under the Company's *2009* Equity Incentive Plan (the *"2009* Plan") as of the IPO that expire, are forfeited or otherwise terminate or that are used to cover the exercise price or applicable tax withholdings. *No* further grants will be made under the *2009* Plan. In addition, the number of shares of common stock reserved for issuance under the *2018* Plan automatically increases on *January 1* of each year, since *January 1, 2019,* by 5% of the total number of shares of the Company's common stock outstanding on *December 31* of the preceding calendar year, or a lesser number of shares determined by the Company's board of directors or a committee of the board of directors appointed to administer the *2018* Plan.

On *August 15, 2025* at the *2025* Annual Meeting of Stockholders, the Company's stockholders approved the Company's amended and restated *2018* Plan (the *"2018* Amended Plan"). The principal changes to the *2018* Plan implemented by the *2018* Amended Plan include amendments to (i) increase the number of shares of the Company's common stock authorized for issuance under the *2018* Plan by an additional 130,000 shares (subject to adjustment for stock splits, stock dividends and similar events), (ii) extend the term of the *2018* Plan to *June 30, 2035 (*the *10*-year anniversary of the Board's adoption of the Amended Equity Plan) and (iii) remove provisions of the *2018* Plan that had been included to comply with the exception for the deductibility of "performance-based compensation" under Section *162*(m) of the Internal Revenue Code of *1986,* as amended, which was repealed by the Tax Cuts and Jobs Act of *2017.* The *2018* Amended Plan became effective upon its approval by the Company's stockholders at the *2025* Annual Meeting.

On *January 1, 2025* and *2026,* the number of shares of common stock reserved for issuance under the *2018* Plan was increased by an aggregate of 10,861 and 164,574 shares, respectively. As of *March 31, 2026*, a total of 187,193 shares of common stock remain available for issuance for future awards under the *2018* Amended Plan.

<u>*2018* Employee Stock Purchase Plan*</u>

The Company's board of directors and stockholders approved and adopted the Genprex *2018* Employee Stock Purchase Plan ("ESPP"), which became effective on *April 3, 2018.* The ESPP has *not* yet been utilized as a benefit available to the Company's employees. The ESPP authorizes the issuance of 105 shares of common stock pursuant to purchase rights that *may* be granted to eligible employees. The number of shares of common stock reserved for issuance under the ESPP is automatically increased on *January 1* of each calendar year, beginning on *January 1, 2019,* by 2% of the total number of shares of common stock outstanding on *December 31* of the preceding calendar year, or a lesser number of shares determined by the administrator of the ESPP. The administrator of the ESPP determined *not* to increase the number of shares reserved for issuance under the ESPP on *January 1, 2026*.

<u>*Stock Options*</u>

As of *March 31, 2026*, Genprex had outstanding stock options to purchase 5,705 shares of common stock that have been granted to various executives, employees, non-employee directors, and independent contractors of the Company, including outstanding stock options to purchase 509 shares of common stock issued as inducement grants, outside of the *2018* Plan, associated with the hiring of new executives in *2021* and *2023.* These options vest immediately or over periods ranging from 12 to 48 months, are exercisable for a period of up to ten years, and enable the holders to purchase shares of the Company's common stock at exercise prices ranging from $900.00 to $19,600.00 per share. The per-share fair values of these options range from $631.00 to $15,860.00.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *15*

------

[**Table of Contents**](#toc)

**GENPREX, INC.**

**NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

 ***MARCH 31, 2026***

The Company did not issue or cancel stock options during the *three* months ended *March 31, 2026*.

The Company did not issue stock options during the *three* months ended *March 31, 2025*. During the *three* months ended *March 31, 2025*, the Company cancelled stock options to purchase 1 share of common stock with an exercise price of $4,280.00 per share in connection with the termination of an employee.

The weighted average remaining contractual term for the outstanding options at *March 31, 2026* and *December 31, 2025* is 3.87 and 4.11 years, respectively.

Stock option activity for each of the *three* months ended *March 31, 2026* and *2025,* respectively, is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***2026*** | ***2026*** | ***2025*** | ***2025*** |
|  | ***Number of*** | ***Weighted Average*** | ***Number of*** | ***Weighted Average*** |
|  | ***Options*** | ***Exercise Price*** | ***Options*** | ***Exercise Price*** |
| Outstanding at January 1, | 5705 | $6081.93 | 5706 | $6081.61 |
| Options expired or cancelled |  |  | 1 | 4280.00 |
| Outstanding at March 31, | 5705 | $6081.93 | 5705 | $6081.93 |

---

<u>*Restricted Stock Units*</u>

During the *three* months ended *March 31, 2026*, the Company (i) withheld 22,611 shares to cover taxes associated with the vesting of employee issued RSUs, and (ii) issued 33,570 shares of common stock associated with the vesting of RSUs to employees.

During the *three* months ended *March 31, 2025*, the Company (i) granted 1,600 RSUs to non-executive employees, (ii) withheld 31 shares to cover taxes associated with the vesting of employee issued RSUs, (iii) cancelled 6 RSUs associated with the termination of an employee, and (iv) issued 200 shares of common stock associated with the vesting of RSUs to employees.

A summary of the RSU activity under the *2018* Plan during the *three* months ended *March 31, 2026* and *2025,* respectively, is presented below. These amounts include RSUs granted to executives, other employees, and board members.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***2026*** | ***2026*** | ***2025*** | ***2025*** |
|  | ***Number of*** | ***Weighted Average*** | ***Number of*** | ***Weighted Average*** |
|  | ***Units*** | ***Grant Date Fair Value*** | ***Units*** | ***Grant Date Fair Value*** |
| Outstanding at January 1, | 141360 | $2.20 | 2124 | $362.71 |
| Restricted stock units granted |  |  | 1600 | 22.05 |
| Restricted stock units vested | 33570 | 2.38 | 200 | 2813.10 |
| Restricted stock units forfeited or cancelled | 22611 | 2.06 | 37 | 2861.35 |
| Outstanding at March 31, | 85179 | $2.17 | 3487 | $39.34 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *16*

------

[**Table of Contents**](#toc)

**GENPREX, INC.**

**NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

 ***MARCH 31, 2026***

<u>*Share-Based Compensation*</u>

For the *three* months ended *March 31, 2026*, the Company's total share-based compensation was approximately $0.12 million, including $0.03 million of R&D expense and approximately $0.08 million of G&A expense, which represents the expected vesting of options or RSUs issued to executives, other employees, board members, and service providers, as well as the issuance of shares to service providers. As of *March 31, 2026*, the Company's total compensation cost related to non-vested time-based stock option awards and warrants granted to executives, other employees, board members, and service providers and *not* yet recognized was approximately $0.16 million. The Company expects to record this stock-based compensation expense over the next *three* years using a graded vesting method. As of *March 31, 2026*, the weighted average term over which these expenses are expected to be recognized is 0.74 years.

For the *three* months ended *March 31, 2025*, the Company's total share-based compensation was approximately $0.18 million, including approximately $0.04 million of R&D expense and approximately $0.14 million of G&A expense, respectively, which represents the expected vesting of options or RSUs issued to executives, other employees, board members, and service providers, as well as the issuance of shares to service providers. As of *March 31, 2025*, the Company's total compensation cost related to non-vested time-based stock option awards and warrants granted to executives, other employees, board members, and service providers and *not* yet recognized was approximately $0.2 million. The Company expects to record this stock-based compensation expense over the next *three* years using a graded vesting method. As of *March 31, 2025*, the weighted average term over which these expenses are expected to be recognized is 0.26 years.

As of *March 31, 2026*, there are no performance-based stock option awards outstanding and one performance-based warrant outstanding issued to a service provider. The Company's total compensation cost related to the non-vested performance-based warrant *not* yet recognized was approximately $0.3 million. The entirety of this warrant *may* be recognized and recorded upon the achievement of certain clinical milestones.

<u>Note *5* - *401*(k) Savings Plan</u>

In *2022,* Genprex established a defined contribution savings plan under Section *401*(k) of the Internal Revenue Code (*"401*(k) Plan") and established an employer matching program for participants in the *401*(k) Plan. The *401*(k) Plan covers all employees who meet defined minimum age and service requirements, and allows participants to defer a portion of their annual compensation on a pre-tax basis. The Company incurred $27,110 and $25,312 of expense for matching contributions to the *401*(k) Plan during the *three* months ended *March 31, 2026* and *March 31, 2025*, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *17*

------

[**Table of Contents**](#toc)

**GENPREX, INC.**

**NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

 ***MARCH 31, 2026***

<u>Note *6* - Commitments and Contingencies</u>

<u>*Commitments*</u>

<u>*MD Anderson Cancer Center*</u>

In *July 2018,* Genprex entered into a *two*-year sponsored research agreement with MD Anderson to sponsor preclinical studies focused on the combination of REQORSA with an immunotherapy with a projected total cost of approximately $2 million. This agreement was extended beyond the original expiration date, expiring in *May 2022* after giving effect to such extension. In *August 2022,* the Company entered into a *three*-year sponsored research agreement with MD Anderson (the *"August 2022* SRA") to sponsor preclinical studies focused on REQORSA and *NPRL2* in oncology to resensitize NSCLC and SCLC to targeted therapies and immunotherapies with an initial projected total cost of approximately $2.9 million. On *June 7, 2024,* the Company amended the *August 2022* SRA with MD Anderson to (i) extend the sponsored research program an additional *six* months, (ii) amend the quarterly budget from approximately $240,000 to $165,000 per quarter, and (iii) amend the total commitment from $2.9 million to approximately $2.76 million. The Company incurred $165,701 of expense from this agreement during the *three* months ended *March 31, 2026*. As of *March 31, 2026*, the Company has paid approximately $2.6 million toward this $2.76 million commitment.

In *2011,* the Company agreed to assume certain contractual and other obligations of IRI in consideration for the sublicense rights, expertise, and assistance associated with certain technologies and intellectual property originally licensed to another party under the *1994* License Agreement with MD Anderson ("Original MD Anderson License Agreement"). These technologies and intellectual property were later sublicensed to IRI (the "IRI Sublicense"). The Company also agreed to pay royalties of 1% on sales of certain licensed products for a period of 21 years following the termination of the later of the Original MD Anderson License Agreement and the IRI Sublicense. The Company assumed patent prosecution costs and an annual minimum royalty of $20,000 payable to the National Institutes of Health ("NIH").

On *March 3, 2021,* the Company entered into an amendment (the "MD License Amendment") to the Patent and Technology License Agreement dated *May 4, 2020,* with MD Anderson. The MD License Amendment grants Genprex a worldwide, exclusive, sublicensable license to an additional portfolio of *six* patents and *one* patent application and related technology for methods for treating cancer by administration of a *TUSC2* therapy in conjunction with EGFR inhibitors or other anti-cancer therapies in patients predicted to be responsive to *TUSC2* therapy. Pursuant to the MD License Amendment, the Company agreed to (i) pay annual maintenance fees ranging from the mid *five* figures to the low *six* figures, (ii) total milestone payments of $6,150,000, (iii) a *one*-time fee in the mid *five* figures and (iv) certain patent-related expenses. The Company did not incur any expense attributable to this agreement for each of the *three* months ended *March 31, 2026* and *2025,* respectively. As of *March 31, 2026*, the Company has paid approximately $525,000 toward the above-described commitment under this agreement.

<u>*National Institutes of Health*</u>

Genprex has a royalty obligation to the National Institutes of Health to be paid upon the Company's receipt of FDA approval using NIH technology. The $240,000 contingent obligation, which increases annually by $20,000, and is $420,000 and $400,000 as of *March 31, 2026* and *December 31, 2025,* respectively, will be recognized if and when it is probable the Company will obtain regulatory approval (the event that triggers the payment obligation).

<u>*New York University*</u>

On *April 25, 2025,* the Company and NYU entered into the NYU License Agreement, which granted Genprex exclusive patent and commercial rights worldwide relating to Genprex's lead drug candidate REQORSA for the potential treatment of mesothelioma. Pursuant to the NYU License Agreement, Genprex agreed to pay: (i) an initial license fee of $5,000, (ii) annual license fees of $35,000 for the *first* and *second* year anniversaries, $25,000 for the *third* anniversary and $50,000 for the *fourth* year and each subsequent year following the *fourth* anniversary of the agreement thereafter, (iii) running low single digit percentage royalties ranging from 1% to 2% of net sales, (iv) certain potential technical milestone payments through regulatory approval up to an aggregate of approximately $400,000, and (v) certain patent-related expenses. The Company did not incur any expense attributable to this agreement for the *three* months ended *March 31, 2026*. As of *March 31, 2026*, Genprex has paid approximately $5,000 toward this commitment.

*<u>University of Michigan</u>*

On *November 11, 2024,* the Company and the University of Michigan entered into the UM License Agreement, which granted Genprex a worldwide, exclusive license to the University of Michigan's patent rights in a co-owned patent application relating to the use of REQORSA in combination with ALK-inhibitors for the treatment of ALK-*EML4* positive translocated lung cancer. Genprex agreed to pay: (i) an initial license issue fee of $30,000, (ii) running low single digit percentage royalties ranging from 1% to 3% of net sales, (iii) minimum annual royalties in a fixed cash amount of $15,000 for *2025* and *2026,* and $30,000 for *2027* and each year thereafter during the term of the UM License Agreement, (iv) a tiered double digit percentage share of non-royalty sublicense income ranging from 10% to 40%, and (v) certain potential clinical milestone payments through FDA regulatory approval up to an aggregate of approximately $350,000 in addition to certain potential commercial sales milestones. The Company incurred $15,000 of expense for each of the *three* months ended *March 31, 2026* and *2025,* respectively. As of *March 31, 2026*, Genprex has paid approximately $30,000 toward this commitment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *18*

------

[**Table of Contents**](#toc)

**GENPREX, INC.**

**NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

 ***MARCH 31, 2026***

<u>*University of Pittsburgh*</u>

Pursuant to the New UP License Agreement dated *February 17, 2025,* by and between Genprex and the University of Pittsburgh, Genprex agreed to pay (i) an initial licensing fee of $10,000, (ii) annual maintenance fees of $65,000 for the first, *second* and *third* years, and $120,000 for the *fourth* year and each subsequent year following the *fourth* anniversary of the agreement thereafter until the anniversary prior to the year of the *first* commercial sale, (iii) royalties ranging from 1.5% to 3% of net sales of licensed technologies, (iv) an annual minimum royalty payment of $250,000 per year beginning in the year of the *first* commercial sale of licensed technology, (v) a share of non-royalty sublicense income of 20%, and (vi) an aggregate of $4,825,000 in milestone payments related to the usage of the licensed technologies to potentially treat Type *1* and Type *2* diabetes. Unless earlier terminated pursuant to its terms, the agreement expires upon the later of (i) *20* years after the *first* commercial sale of the licensed technology thereunder and (ii) expiration of the last valid claim under the patent rights. The Company incurred $65,000 and $10,000 of expense for the *three* months ended *March 31, 2026* and *2025,* respectively. As of *March 31, 2026*, Genprex has paid approximately $75,000 toward this commitment.

<u>*UTHealth Houston*</u>

On *May 2, 2025,* the Company and UTHealth Houston entered into the UTH License Agreement, which granted Genprex exclusive patent and commercial rights worldwide relating to Genprex's lead drug candidate REQORSA for the potential treatment of glioblastoma. Pursuant to the UTH License Agreement, Genprex agreed to pay: (i) an initial license issue fee of $10,000 along with additional, staggered upfront license fees totaling another $40,000 and an annual license management fee of $3,000, (ii) running low single digit percentage royalties ranging from 0.10% to 0.25% of net product sales, (iii) minimum annual royalty of $25,000 beginning after the *first* year in which royalties obligations commence pursuant to the UTH License Agreement, (iv) certain potential clinical and regulatory milestone payments through FDA and international regulatory approvals up to an aggregate of approximately $360,000, and (v) certain patent-related expenses. The Company did *not* incur any expense attributable to this agreement for the *three* months ended *March 31, 2026*. As of *March 31, 2026*, Genprex has paid approximately $20,000 toward this commitment.

<u>*Contingencies*</u>

From time to time, the Company *may* become subject to threatened and/or asserted claims arising in the ordinary course of its business. Management is *not* aware of any pending matters, either individually or in the aggregate, that are reasonably likely to have a material impact on the Company's financial condition, results of operations or liquidity.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *19*

------

[**Table of Contents**](#toc)

**GENPREX, INC.**

**NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

 ***MARCH 31, 2026***

<u>Note *7* - Segment Reporting</u>

Operating segments are defined as components of an entity for which separate discrete financial information is made available and that is regularly evaluated by the chief operating decision maker ("CODM") in making decisions regarding resource allocation and assessing performance. The Company manages its operations as a single segment (the "Segment") for the purposes of assessing performance and making operating decisions. The CODM of the Segment is the Company's Chief Executive Officer. The Segment is focused on pioneering the discovery and development of gene therapies for use in patient populations with unmet medical needs. The accounting policies for the Segment are the same as those described in Note *2,* Summary of Significant Accounting Policies. The CODM assesses the performance of the Segment and decides how to allocate resources based on net loss that is reported on the condensed consolidated statements of operations. Further, the following represents information about Segment loss and significant Segment expenses:

---

| | | |
|:---|:---|:---|
|  | ***Three Months Ended*** | ***Three Months Ended*** |
|  | ***March 31,*** | ***March 31,*** |
|  | ***2026*** | ***2025*** |
| Revenues | $— | $— |
| Less: |  |  |
| Clinical and regulatory | 1690402 | 1706705 |
| Manufacturing | 612212 | 483065 |
| Research | 408834 | 308327 |
| General and administrative support | 1664101 | 1286422 |
| Non-cash expenses(1) | 118635 | 184773 |
| Other income | 31748 | 4771 |
| Plus: |  |  |
| Realized and unrealized gain (loss) | 541 | (80) |
| Segment and net loss | $4461895 | $3964601 |

---

(*1*) Includes $118,634 and $184,773 of stock-based compensation expense for the *three* months ended *March 31, 2026* and *2025,* respectively.

<u>Note *8* - Subsequent Events</u>

The Company has evaluated subsequent events through the filing of this Quarterly Report on Form *10*-Q and determined that there have been *no* recognized subsequent events that have occurred that would require adjustments to the Company's disclosures in the condensed consolidated financial statements. The following are nonrecognized subsequent events through the filing of this Quarterly Report on Form *10*-Q.

<u>*Share Issuances*</u>

On *April 1, 2026,* Genprex issued 5,000 shares of its common stock to the Chairman of its Scientific Advisory Board in consideration for services.

*<u>At-The-Market Offering</u>*

From *April 1, 2026* through the date of filing of this Quarterly Report on Form *10*-Q, Genprex has sold 1,536,546 shares of its common stock for aggregate net proceeds to the Company totaling approximately $1.90 million under the *2023* ATM Facility.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *20*

------

[**Table of Contents**](#toc)

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

*You should read the following Management's Discussion and Analysis of Financial Condition and Results of Operations (*"*MD&A*"*) together with our interim condensed consolidated financial statements and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled* "*Risk Factors*" *included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, in this filing, and in our other SEC filings, as may be amended, supplemented or superseded from time to time by other reports we file with the SEC. All amounts in this report are in United States (*"*U.S.*"*) dollars, unless otherwise noted.*

**CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA**

This Quarterly Report on Form 10-Q (this "Quarterly Report") contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). This Quarterly Report contains forward-looking statements that involve substantial risks and uncertainties. Unless the context requires otherwise, references to "Genprex," the "Company," "we," "us" or "our" in this Quarterly Report refer to Genprex, Inc. Any statements in this Quarterly Report about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as "believe," "will," "expect," "anticipate," "estimate," "intend," "plan," "would" and similar expressions. For example, statements concerning financial condition, possible or assumed future results of operations, growth opportunities, industry ranking, plans and objectives of management, markets for our product candidates and their respective targeted indications, including estimated or projected size or other expected trends in such markets, and any other statements involving anticipated or expected market or industry projections, statements regarding markets for our common stock and future management and organizational structure and statements about our current or future product candidates and their development, our beliefs regarding their preclinical or clinical profile or efficacy, and the regulatory approval process and pathway and the timing thereof, are all forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement.

Any forward-looking statements are qualified in their entirety by reference to the risk factors discussed throughout this Quarterly Report. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include but are not limited to:

● Market conditions;

---

| | |
|:---|:---|
| ● ● ● ●  | Our capital position;<br>Our ability to raise additional future financing and possible lack of financial and other resources, and our ability to continue to support and fund our preclinical and clinical development programs and growth of our business;<br>Our ability to continue as a going concern;<br>Our ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and maintain the listing of our common stock; |

---

● Our ability to compete effectively and with larger and/or better-financed biotechnology and pharmaceutical companies;

● Our uncertainty of developing marketable products;

● Our ability to develop and commercialize our products;

● Our ability to obtain regulatory approvals;

● Our ability and third-parties' ability to maintain and protect intellectual property rights;

&nbsp;&nbsp;&nbsp;&nbsp;

● The effects and impacts of public health crises such as epidemics or outbreaks, which could significantly disrupt and have a materially adverse effect upon on our business, our clinical trials and our research programs; as well as on healthcare systems or the global economy as a whole;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 21

------

[**Table of Contents**](#toc)

● The success of our clinical trials through all phases of clinical development, including the ability of our third-party suppliers or manufacturers to supply or manufacture our products on a timely, consistent basis in a manner sufficient and appropriate as is commensurate to meet our clinical trial timing, courses of treatment, and other requisite fulfillment considerations necessary to adequately advance our development programs;

&nbsp;&nbsp;&nbsp;&nbsp;

● Our ability to conduct and complete our clinical trials in accordance with projected timelines;

---

| | |
|:---|:---|
| ● ●  | Any delays in regulatory review and approval of our current and future product candidates;<br>The effects of any strategic research and development prioritization initiatives, and any other strategic alternatives or other efforts that we take or may take in the future that are aimed at optimizing and re-focusing our diabetes, oncology and/or other clinical development programs including prioritization of resources, and the extent to which we are able to implement such efforts and initiatives successfully to achieve the desired and intended results thereof, including successful implementation of the separation of our diabetes clinical development program, including the anticipated benefits of the internal reorganization, the expected timing of the reorganization and/or if it is completed as contemplated or at all; |

---

● Our dependence on third-party suppliers or manufacturers to supply or manufacture our key ingredients and/or raw materials, products and/or product components and successfully carry out a sustainable, reproducible and scalable manufacturing process in accordance with specifications or applicable regulations;

● Our ability to control product development costs;

● Our ability to attract and retain key employees;

● Our ability to enter into new strategic collaborations, licensing or other arrangements;

● Changes in government regulation affecting product candidates that could increase our development costs;

● Our involvement in patent, trademark and other intellectual property litigation that could be expensive and divert management's attention;

● The possibility that there may be no market acceptance for our products; and

● Changes in third-party reimbursement policies which could adversely affect potential future sales of any of our products that are approved for marketing.

The foregoing list sets forth some, but not all, of the factors that could affect our ability to achieve results described in any forward-looking statements, which speak only as of the date of this Quarterly Report or the date of the document incorporated by reference into this Quarterly Report. Except as required by law, we assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this Quarterly Report or to reflect the occurrence of unanticipated events. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements contained in this Quarterly Report. All forward-looking statements are expressly qualified in their entirety by the cautionary statements contained in this section.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 22

------

[**Table of Contents**](#toc)

**Overview**

We are a clinical stage gene therapy company pioneering the development of gene-based therapies for large patient populations with unmet medical needs. Our oncology platform utilizes our systemic, non-viral ONCOPREX® Delivery System which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. The product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. Our diabetes technology is designed to work in Type 1 diabetes by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In Type 2 diabetes, our technology is believed to work by replenishing and rejuvenating exhausted beta cells that make insulin.

*<u>Oncology Platform</u>*

Our lead oncology drug candidate, REQORSA® Gene Therapy (generic name: *quaratusugene ozeplasmid*), previously referred to as GPX-001, is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer ("NSCLC") and Small Cell Lung Cancer ("SCLC"). REQORSA has multimodal effects on cancer cells. It has a mechanism of action whereby it decreases cancer growth by decreasing glucose metabolism, interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and increases the immune response against cancer cells. In preclinical studies, REQORSA has been shown to be complementary with targeted drugs and immunotherapies. Our strategy is to develop REQORSA in combination with currently approved therapies and we believe REQORSA's unique attributes position it to provide treatments that improve on these current therapies for patients with NSCLC, SCLC, and possibly other cancers.

The TUSC2 gene, which is the key component of REQORSA and plays a vital role in cancer suppression and normal cell metabolism, is one of a series of genes on the short arm of Chromosome 3 whose therapeutic use is covered by our exclusive worldwide licenses from The University of Texas MD Anderson Cancer Center ("MD Anderson"). We believe that our ONCOPREX Delivery System allows for the delivery of a number of cancer-fighting tumor suppressor genes, alone or in combination with other cancer therapies, to combat multiple types of cancer and we are in early stages of discovery programs to identify other cancer candidates. Since not all patients respond to REQORSA, we have been collaborating with researchers at MD Anderson to identify biomarkers that might predict a strong positive response or a lack of response to REQORSA in patients with lung cancer. This preclinical effort has led to the identification of two proteins whose expression appears to predict response to REQORSA. This work, titled "*TROP2 and PTEN are biomarkers of primary resistance to TUSC2 gene therapy in non-small cell lung cancer*" was accepted for a poster presentation at the meeting of the American Association of Cancer Research in April 2026. These findings suggest that TROP2 and PTEN may serve as biomarkers to predict TUSC2 response and guide therapeutic strategies in NSCLC. TROP2 (trophoblast cell-surface antigen 2) is a transmembrane glycoprotein that functions as a cell surface receptor. TROP2 overexpression in adult tissues is a hallmark of many solid tumors, making it a major target for modern cancer therapies. PTEN (phosphatase and tensin homolog) is a tumor suppressor gene that serves as a multi-functional cancer biomarker in a number of cancers, with potential for risk assessment, diagnosis and treatment planning. Validation in specimens from clinical trials will be needed to determine whether these potential biomarkers predict clinical response. In April 2026, we entered into a new sponsored research agreement with MD Anderson to study biomarkers that may predict patient response to REQORSA. We are testing patient samples from our clinical trials for selected biomarkers to determine if sensitivities exist among our existing patient population in an effort to guide patient selection and optimize clinical outcomes.

*Acclaim – 1*: The Acclaim-1 study is a Phase 1/2 clinical trial that has three portions - a Phase 1 dose escalation portion, a Phase 2a expansion portion, and a Phase 2b randomized portion. We currently are enrolling and treating patients in the Phase 2a expansion portion of our Phase 1/2 Acclaim-1 clinical trial. The Acclaim-1 trial uses a combination of REQORSA and AstraZeneca's Tagrisso® (*osimertinib*) in patients with late-stage NSCLC who have activating epidermal growth factor receptor ("EGFR") mutations and disease progression on treatment with Tagrisso or Tagrisso-containing regimens. Following the May 2023 completion of the Phase 1 dose escalation portion of the study, the Acclaim-1 Safety Review Committee ("Acclaim-1 SRC") approved advancement from the Phase 1 dose escalation portion to the Phase 2a expansion portion of the study. Based on a review of safety data which showed no dose limiting toxicities ("DLTs"), the Acclaim-1 SRC determined the recommended Phase 2 dose ("RP2D") of REQORSA to be 0.12 mg/kg administered every 21 days. This was the highest dose level delivered in the Phase 1 portion of the study and is twice the highest dose level delivered in our prior clinical trial combining REQORSA with Tarceva® (*erlotinib*) for the treatment of late-stage lung cancer. There were three patients out of the twelve originally enrolled in the Phase 1 dose escalation portion of the study who had prolonged progression-free survival ("PFS"). One patient attained a partial remission after the second course of REQORSA and Tagrisso and has maintained this response through 64 courses of treatment (approximately 48 months) and this patient continues to receive REQORSA and Tagrisso treatment to date. A second patient had stable disease without disease progression through 32 courses of treatment (approximately 24 months), but then had disease progression and REQORSA treatment was stopped. A third patient had stable disease without disease progression through 14 courses of treatment (approximately 10 months) before disease progression and is no longer receiving treatment. The results of the Phase 1 dose escalation portion of the study were published in *Clinical Lung Cancer*, a peer-reviewed journal covering various aspects of clinical and translational research of lung cancer, in January 2026. We opened the Phase 2a expansion portion of the study and enrolled and dosed the first patient in January 2024. The Phase 2a expansion portion of the trial is expected to enroll approximately 33 patients, all of whom had disease progression on Tagrisso or Tagrisso-containing regimens. There will be an interim analysis following the treatment of 19 patients in the Phase 2a portion of the Acclaim-1 study. We expect to complete the enrollment of the first 19 patients for interim analysis in the Phase 2a expansion portion of the study in the first half of 2026 and expect the interim analysis in the second half of 2026.

The Food and Drug Administration ("FDA") has granted Fast Track Designation for the Acclaim-1 treatment combination of REQORSA and Tagrisso in NSCLC patients who have progressed on Tagrisso treatment.

The Phase 2a expansion portion of the Acclaim-1 study provides us the advantage of early insight into drug effectiveness in defined and distinct patient populations at the maximum tolerated dose or RP2D in order to better evaluate efficacy and increase the likelihood of a successful randomized Phase 2 trial which will follow the expansion portion of the study.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 23

------

*Acclaim* – *3*: The Acclaim-3 study has two portions - a Phase 1 dose escalation portion and a Phase 2 expansion portion. We are currently enrolling and treating patients in the Phase 2 expansion portion of our Phase 1/2 Acclaim-3 clinical trial. The Acclaim-3 clinical trial uses a combination of REQORSA and Genentech, Inc.'s Tecentriq® (*atezolizumab*) as maintenance therapy for patients with extensive stage small cell lung cancer ("ES-SCLC") who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. Patients are treated with REQORSA and Tecentriq until disease progression or unacceptable toxicity is experienced. In December 2024, we announced that we had completed the Phase 1 dose escalation portion of the Acclaim-3 clinical trial. Based on full safety data, which showed no DLTs, the Acclaim-3 Safety Review Committee ("Acclaim-3 SRC") determined that the RP2D of REQORSA will be 0.12 mg/kg administered every 21 days, which was the highest dose level delivered in the Phase 1 portion of the trial, and approved the opening of the Phase 2 expansion portion of the trial. Although decreases in tumor size are not expected during maintenance therapy with atezolizumab alone, there were two patients out of the six enrolled in the Phase 1 dose escalation portion of the study who had marked decreases in measurable disease. We previously reported that the first patient treated in the Phase 1 dose escalation portion of the Acclaim-3 trial had a partial remission, which is defined as at least a thirty percent (30%) decrease in tumor size, from prior to the start of maintenance therapy to the time of the CT scan performed after two cycles of maintenance therapy. A CT scan performed after four cycles of maintenance therapy (three months), confirmed that the patient still had a 30% decrease in tumor size in measurable lesions; however, one lesion not previously measurable had grown in size, thus leading to a conclusion of disease progression at that time. Another patient in the Phase 1 dose escalation portion of the Acclaim-3 trial had a twenty-three percent (23%) decrease in tumor size from prior to the start of maintenance therapy to the time of the CT scan performed after two cycles of maintenance therapy. This patient received seven cycles of study therapy before progressing after 4.2 months. In addition, one patient in the Phase 1 dose escalation portion of the study achieved an unconfirmed partial remission after 24 cycles of therapy and continues to receive study treatment in the trial after more than 19 months. We anticipate that the Phase 2 expansion portion will enroll approximately 50 patients at approximately 10 to 15 U.S sites. Patients will be treated with REQORSA and Tecentriq until disease progression or unacceptable toxicity is experienced. The primary endpoint of the Phase 2 portion is to determine the 18-week progression-free survival rate from the start of maintenance therapy with REQORSA and Tecentriq in patients with ES-SCLC. Patients will also be followed for survival. A Phase 2 futility analysis will be performed after the 25th patient enrolled and treated reaches 18 weeks of follow up. We expect to complete enrollment of the first 25 patients for interim analysis in the Phase 2 expansion portion of the study in the first half of 2026 and expect the interim analysis in the second half of 2026.

The Acclaim-3 clinical trial has received FDA Fast Track Designation for this patient population and Acclaim-3 has also received an FDA Orphan Drug Designation.

*<u>Diabetes Gene Therapy</u>*

In diabetes, we have exclusively licensed from the University of Pittsburgh of the Commonwealth System of Higher Education ("University of Pittsburgh" or "UP") multiple technologies relating to the development of a gene therapy product for each of Type 1 and Type 2 diabetes. The same novel approach is used in each of Type 1 and Type 2 diabetes whereby an adeno-associated virus ("AAV") vector containing the Pdx1 and MafA genes is administered directly into the pancreatic duct. In humans, this can be done with a routine endoscopy procedure. Our diabetes product candidates are currently being evaluated and optimized in preclinical studies at the University of Pittsburgh. GPX-002 is being developed for the treatment of both Type 1 diabetes and Type 2 diabetes. GPX-002 for Type 1 diabetes is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to work by replenishing and rejuvenating exhausted beta cells that make insulin. We are currently working with the University of Pittsburgh on species analyses for the animal models as well as other regulatory and clinical strategic planning, including the initiation of research in Type 2 diabetes animal models. In December 2025, we also executed on our strategic goal to submit a meeting request to the FDA by the end of the year to discuss the necessary Investigational New Drug ("IND")-enabling preclinical studies, an important step before potentially initiating clinical trials in humans. See the discussion captioned "Recent Developments – Diabetes Gene Therapy Updates" below for more information on the Company's meeting with the FDA which occurred in February 2026. In May 2025, following the completion of our August 2022 sponsored research agreement with UP, we entered into a new sponsored research agreement with UP to study Type 1 diabetes and Type 2 diabetes in animal models. The new sponsored research agreement also includes a revised research plan to encompass our most recent technologies to which we originally acquired exclusive rights from UP in July 2023 as amended and restated in the comprehensive New UP License Agreement in February 2025 (as defined and described below). These include a MafB promoter to drive expression of the Pdx1 and MafA transcription factors that can potentially be used for both Type 1 and Type 2 diabetes. See also "Note 6 – Commitments and Contingencies" to our unaudited condensed consolidated financial statements in this Quarterly Report on Form 10-Q.

On February 17, 2025, we and the University of Pittsburgh entered into an amended and restated Exclusive License Agreement (the "New UP License Agreement"), which updated and consolidated into a single agreement our prior license agreements with UP. Pursuant to the New UP License Agreement, UP granted to us a worldwide, exclusive license for certain patents and related technology, collectively referred to as the "Licensed Technology," and a worldwide, non-exclusive license to use certain related know-how. The Licensed Technology covered by the New UP License Agreement is based on the same general gene therapy approach as covered under our prior license agreements with UP (less the previously-licensed macrophage technology), whereby an adeno-associated virus vector containing the Pdx1 and MafA genes is administered directly into the pancreatic duct. More specifically, the Licensed Technology covered by the New UP License Agreement is related to a gene therapy for both Type 1 diabetes and Type 2 diabetes using the genes of the Pdx1 and MafA transcription factors controlled by insulin, glucagon and MafB promoters.

In February 2023, our research collaborators at UP presented preclinical data in a non-human primate ("NHP") model of Type 1 diabetes highlighting the therapeutic potential of GPX-002 at the 16th International Conference on Advanced Technologies & Treatments for Diabetes ("ATTD 2023") in Berlin, Germany. The statistically significant study results showed the treated animals had decreased insulin requirements, increased c-peptide levels, and improved glucose tolerance compared to baseline. In April 2023, the Company hosted a Key Opinion Leader virtual event entitled "Novel Gene Therapy to Treat Type 1 Diabetes," which discussed preclinical data reported at ATTD 2023 supporting gene therapy to treat Type 1 diabetes. In June 2025, our collaboration partners had two presentations at the 2025 American Diabetes Association ("ADA") 85th Scientific Sessions. Our research collaborators from UP were invited to give an oral presentation highlighting their work in NHP models of Type 1 diabetes. In addition, our contract development and manufacturing organization collaborators presented a poster on a non-viral lipid nanoparticle delivery system that would allow a patient to receive multiple treatments.

**Recent Developments**

*<u>Diabetes Gene Therapy Updates</u>*

As previously disclosed, in December 2025 we submitted a request to meet with the FDA to discuss the necessary IND-enabling preclinical studies for our Type 1 diabetes gene therapy program, an important step before potentially initiating clinical trials in humans. On February 19, 2026, we met with the FDA and received feedback which aligned with our expectations and plans. Following the FDA meeting and receipt of the official meeting minutes, we plan to continue with preclinical animal studies, as expected, which will allow us to finalize the design and initiate future toxicology studies. Subsequent data from toxicology studies are expected to enable IND filing. Toxicology studies are a required step of drug development, ensuring that new treatments are evaluated in animal models before human use in order to identify potential risks, determine safe dosages and monitor for side effects. Additionally, we plan to begin clinical scale production in a current Good Manufacturing Practices ("cGMP") compliant facility, allowing us to accelerate our manufacturing processes necessary for IND-enabling preclinical studies and clinical trials. We are also continuing work with third-party contract development and manufacturing organizations ("CDMOs") and research partners to optimize constructs and evaluate alternative second-generation approaches including different AAV and non-viral constructs.

*<u>At-the-Market Offering Program</u>*

On December 13, 2023, we entered into an At The Market ("ATM") Offering Agreement (the "Sales Agreement") with H.C. Wainwright & Co., LLC, serving as agent (the "Agent") with respect to an ATM offering program (the "2023 ATM Facility") under which we may offer and sell through the Agent, from time to time at our sole discretion, up to such number or dollar amount of shares (the "Shares") of our common stock, as registered on the prospectus supplement covering the 2023 ATM Facility offering, as may be amended or supplemented from time to time, including pursuant to any new or successor registration statement that we may file and such applicable prospectuses and prospectus supplements forming a part thereof. We have agreed to pay the Agent a commission equal to three percent (3%) of the gross sales proceeds of any Shares sold through the Agent under the Sales Agreement, and also have provided the Agent with customary indemnification and contribution rights. From April 1, 2026 through the date of filing of this Quarterly Report on Form 10-Q, we have sold 1,536,546 Shares of our common stock for net proceeds to us totaling approximately $1.90 million through the Agent under the Sales Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 24

------

**Recently Issued Accounting Pronouncements**

A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed below and in Note 2 to our unaudited condensed consolidated financial statements appearing in this Quarterly Report on Form 10-Q.

**Critical Accounting Estimates**

Our unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the U.S. ("US GAAP"). The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, and the reported amounts of expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

We believe that the following accounting policies and estimates are the most critical to aid in fully understanding and evaluating our reported financial results, and they require our most difficult, subjective or complex judgments, resulting from the need to make estimates about the effect of matters that are inherently uncertain.

***Research and Development Costs***

We record accrued expenses for costs invoiced from research and development activities conducted on our behalf by third-party service providers, which include the conduct of preclinical studies and clinical trials and contract research, manufacturing, and testing activities. We record the costs of research and development activities based upon the amount of services provided, and we include these costs in accrued liabilities in the unaudited condensed consolidated balance sheets and within research and development expense in the unaudited condensed consolidated statements of operations. These costs are a significant component of our research and development expenses. Purchased materials to be used in future research are valued at cost and capitalized and included in research and development supplies. The costs of materials that were acquired for a particular research and development activity and have no alternative future use are expensed in the period acquired.

We estimate the amount of work completed through discussions with internal personnel and external service providers as to the progress or stage of completion of the services and the agreed-upon fee to be paid for such services. We make significant judgments and estimates in determining the accrued balance in each reporting period. As actual costs become known, we adjust our accrued estimates. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed, the number of patients enrolled and the rate of patient enrollment in any of our clinical trials may vary from our estimates and could result in our reporting amounts that are too high or too low in any particular period. Our accrued expenses are dependent, in part, upon the receipt of timely and accurate reporting from contract research organizations ("CROs") and other third-party service providers.

***Income Taxes***

Deferred tax assets or liabilities are recorded for temporary differences between financial statement and tax basis of assets and liabilities, using applicable rates in effect for the year in which the differences are expected to reverse. A valuation allowance is recorded if it is more likely than not that a deferred tax asset will not be realized. We have provided a full valuation allowance on our deferred tax assets, which primarily consist of cumulative net operating losses from April 1, 2009 (inception) to March 31, 2026. Due to our history of operating losses since inception and losses expected to be incurred in the foreseeable future, a full valuation allowance was considered necessary.

***Impairment of Long-Lived Assets***

Management evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be realizable or at a minimum annually during the fourth quarter of the year. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared to the asset's carrying value to determine if an impairment of such asset is necessary. The effect of any impairment would be to expense the difference between the fair value of such asset and its carrying value based upon discounted cash flows.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25

------

**Components of our Results of Operations and Financial Condition**

***Operating expenses***

We classify our operating expenses into three categories: research and development, general and administrative, and depreciation.

***Research and development***. Research and development expenses consist primarily of:

• costs incurred to conduct research, such as the discovery and development of our current and potential product candidates;

• costs related to the production and storage of supplies for engineering purposes and storage and usage of clinical supplies, including waste created in the process of producing clinical materials, spoilage, and testing of clinical materials;

• costs related to the use of contract manufacturers, manufacturing consultants, testing organizations, cold-storage facilities, and logistics service providers;

• fees paid to clinical consultants, clinical trial sites and vendors, including CROs in conjunction with implementing and monitoring our clinical trials and acquiring and evaluating clinical trial data, including all related fees, such as patient screening fees, laboratory work, and statistical compilation and analysis; 

• costs related to compliance with drug development regulatory requirements; and

• costs related to staffing and personnel associated with research and development activities, including wages, taxes, benefits, leases, overheads, supplies, and share-based compensation.

We recognize all research and development costs as they are incurred except those capitalized with alternative further use. Clinical trial costs, contract manufacturing and other development costs incurred by third-parties are expensed as the contracted work is performed.

We expect our research and development expenses to increase in the future as we (i) advance our current and future product candidates into and through clinical trials, (ii) transition some of our manufacturing activities to new vendors for a variety of reasons, such as to incorporate more advanced processes and scale production, including any additional work that has been or may be required to successfully adapt our process to these new processes, (iii) pursue regulatory approval of our current and potential product candidates in the U.S. and Europe, and (iv) expand our research programs to include new therapies and new therapy combinations. The process of conducting the necessary pre-clinical and clinical research to obtain regulatory approval is costly and time-consuming. The actual probability of success for our current and potential product candidates may be affected by a variety of factors including the quality of our current and potential product candidates, early clinical data, investment in our clinical program, competition, manufacturing capability and commercial viability, and limited contracted partners. We may never succeed in achieving regulatory approval for any of our current or future product candidates. As a result of the uncertainties discussed above, we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of our product candidates, if at all. However, we continue to evaluate ways to optimize our clinical and research programs and operational strategies, as part of our ongoing prioritization initiative. Additionally, we are considering various strategic alternatives and opportunities to enhance stockholder value.

***General and administrative****.* General and administrative expense consists of personnel related costs, which include administrative and executive salaries, as well as the costs of professional services, such as accounting and legal, travel, facilities, information technology and other administrative expenses. We expect our general and administrative expense to increase in future periods due to the anticipated growth of our business and related infrastructure as well as accounting, insurance, investor relations, and other costs associated with being a public company.

***Depreciation****.* Depreciation expense consists of depreciation from our fixed assets consisting of our property, equipment, and furniture. We depreciate our assets over their estimated useful life. We estimate furniture and computer and office equipment to have a three to five year life.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 26

------

**Results of Operations**

***Comparison of the Three Months Ended March 31, 2026 and 2025***

The following summarizes our results of operations for the three months ended March 31, 2026 and 2025.

**Research and Development Expense**

Research and development ("R&D") expense for the three months ended March 31, 2026 was $2,745,945, compared to $2,539,993 for the three months ended March 31, 2025, an increase of $205,952, or 8%. This increase was primarily due to (i) differences in enrollment rates and administration of services associated with the Acclaim-1 and Acclaim-3 clinical trials during each of the periods, (ii) a slight increase in manufacturing of clinical materials and research materials, (iii) a slight increase in preclinical research and R&D discovery programs, and (iv) increase in R&D overheads associated with the accrual of bonuses.

**General and Administrative Expense**

General and administrative ("G&A") expense for the three months ended March 31, 2026 was $1,748,239, compared to $1,429,299 for the three months ended March 31, 2025, an increase of $318,940, or 22%. This increase was primarily due to (i) an increase in corporate franchise tax expense as a result of the one-for-fifty (1:50) reverse stock split of our issued and outstanding shares of common stock effected on October 21, 2025 (the "2025 Reverse Split"), (ii) a slight increase in the expense amount associated with professional service providers, and (iii) an increase in G&A overheads associated with the accrual of bonuses.

**Other Income.** Other income was $31,748 and $4,771 for the three months ended March 31, 2026 and 2025, respectively, representing an increase of $26,977. The increase was primarily due to larger cash balances held in interest bearing accounts for the three months ended March 31, 2026 compared to the three months ended March 31, 2025.

**Depreciation Expense.** There was no depreciation expense for the three months ended March 31, 2026 and March 31, 2025.

**Net Loss.** We had a net loss of $4,461,895 and $3,964,601 for the three months ended March 31, 2026 and 2025, respectively, representing an increase of $497,294, or 13%. The increase in net loss between these periods was primarily due to (i) differences in enrollment rates and administration of services associated with the Acclaim-1 and Acclaim-3 clinical trials during each of the periods, (ii) a slight increase in manufacturing of clinical materials and research materials, (iii) a slight increase in preclinical research and R&D discovery programs, (iv) increase in R&D and G&A overheads associated with the accrual bonuses, (v) an increase in corporate franchise tax expense as a result of the 2025 Reverse Split, and (vi) a slight increase in the expense amount associated with professional service providers.

**Liquidity and Capital Resources**

From inception through March 31, 2026, we have never generated revenue from product sales and have incurred net losses in each year. As of March 31, 2026, we had an accumulated deficit of $175,490,291. We have funded our operations primarily through the sale and issuance of capital stock.

During the three months ended March 31, 2026, we sold 5,714,798 Shares of common stock for aggregate gross proceeds of approximately $13.80 million (resulting in aggregate net proceeds of approximately $13.36 million after offering expenses), pursuant to our 2023 ATM Facility. From April 1, 2026 through the date of filing of this Quarterly Report on Form 10-Q, we sold 1,536,546 Shares of common stock for aggregate gross proceeds of approximately $1.96 million (resulting in aggregate net proceeds of approximately $1.90 million after offering expenses), pursuant to our 2023 ATM Facility.

For the year ended December 31, 2025, we sold (i) 1,602,490 Shares of common stock for net proceeds of approximately $10.8 million pursuant to our 2023 ATM Facility, (ii) 772,867 shares of common stock (inclusive of the 23,737 commitment shares issued pursuant to the Purchase Agreement (as defined below)) for aggregate net proceeds of approximately $5.3 million, pursuant to our 2025 ELOC Facility (as defined below), (iii) completed a registered direct offering in which we sold (x) 243,622 shares of our common stock, and (y) warrants exercisable for up to an aggregate of 487,244 shares of our common stock ("October 2025 Private Warrant Shares I"), for net proceeds of approximately $2.5 million, and (iv) completed a registered direct offering in which we sold (x) 377,780 shares of our common stock, and (y) warrants exercisable for up to an aggregate of 755,560 shares of our common stock ("October 2025 Private Warrant Shares II"), for net proceeds of approximately $3.1 million. See also "Note 4 - Equity - Registered Direct Offerings" to our unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.

On June 11, 2025, we entered into an equity line of credit ("ELOC") purchase agreement, dated June 11, 2025 (the "Purchase Agreement"), with Lincoln Park Capital Fund, LLC ("Lincoln Park"), pursuant to which Lincoln Park committed to purchase from us up to $12.5 million in shares of our common stock (subject to certain conditions and limitations contained in the Purchase Agreement) from time to time at our sole discretion over the 24-month term of the Purchase Agreement (the "2025 ELOC Facility"). Sales of shares of common stock to Lincoln Park under the Purchase Agreement will depend on a variety of factors to be determined by us from time to time, including, among others, market conditions, the trading price of our common stock and our determination as to the appropriate sources of funding for our operations. See also "Note 4 - Equity – Equity Line of Credit" to our unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.

On December 13, 2023, we entered into an At The Market ("ATM") Offering Agreement (the "Sales Agreement") with H.C. Wainwright & Co., LLC, serving as agent (the "Agent") with respect to an at-the-market offering program (our "2023 ATM Facility") under which we may offer and sell through the Agent, from time to time at our sole discretion, up to such number or dollar amount of shares of our common stock (the "Shares") as registered on the prospectus supplement covering the 2023 ATM Facility offering, as may be amended or supplemented from time to time, including any new or successor registration statement that we may file and such applicable prospectuses and prospectus supplements forming a part thereof. We have agreed to pay the Agent a commission equal to three percent (3%) of the gross sales proceeds of any Shares sold through the Agent under the Sales Agreement, and also have provided the Agent with customary indemnification and contribution rights. See also "Note 4 - Equity - At-The-Market Offering" to our unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 27

------

[**Table of Contents**](#toc)

As of March 31, 2026, we had $18,049,255 in cash and cash equivalents.

We do not expect to generate revenue from product sales unless and until we successfully complete development of, obtain regulatory approval for and begin to commercialize one or more of our current or future product candidates, which we expect will take a number of years and which is subject to significant uncertainty. Accordingly, we anticipate that we will need to raise additional capital to fund our future operations, which include conducting our Acclaim-1 and Acclaim-3 clinical trials (of which both are currently enrolling) and completing preclinical work for potential other oncology candidates and completing preclinical work and conducting clinical trials for our diabetes program. We expect interim enrollment of the Phase 2a expansion portion of the Acclaim-1 trial to be completed in the first half of 2026. We expect interim enrollment in the Phase 2 dose expansion portion of the Acclaim-3 trial to be completed in the first half of 2026. Until such time as we can generate substantial revenue from product sales, if ever, we expect to finance our operating activities through a combination of equity offerings, drawdowns on our 2023 ATM Facility pursuant to our Sales Agreement with the Agent, sales pursuant to our 2025 ELOC Facility, and debt financings and we may seek to raise additional capital through strategic collaborations or transactions. However, we may be unable to raise additional funds or enter into such arrangements when needed on favorable terms, or at all, which would have a negative impact on our financial condition and could force us to delay, limit, reduce or terminate our research and development programs or commercialization efforts or grant rights to others to develop or market product candidates that we would otherwise prefer to develop and market ourselves. Failure to receive additional funding could cause us to curtail or cease our operations. Furthermore, even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital due to favorable market conditions or strategic considerations. As a result of our recurring losses from operations and the need for additional financing to fund our operating and capital requirements, there is uncertainty regarding our ability to maintain liquidity sufficient to operate our business effectively over the next 12 months, which raises substantial doubt as to our ability to continue as a going concern.

Based on our current cash, we estimate that we will be able to fund our expenditure requirements for our current operations and planned clinical trial activities into the second half of 2027. We have based these estimates on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently plan due to incorrect assumptions or due to a decision to expand our activities beyond those currently planned. We have experienced delays in clinical trial enrollment as a result of competition for patients and previously experienced delays due to additional time required in connection with transitions to new third party CDMOs and the manufacture of final drug product. Delays in the conduct of our trials could result in utilizing our capital resources sooner without advancing our clinical trials as anticipated.

The following table sets forth the primary sources and uses of cash during the three months ended March 31, 2026, and 2025:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2026** | **2025** |
| Net cash used in operating activities | $(3138457) | $(4161424) |
| Net cash used in investing activities |  |  |
| Net cash provided by financing activities | 13356857 | 6028102 |
| Net increase in cash and cash equivalents | $10218400 | $1866678 |

---

*Cash used in operating activities*

Net cash used in operating activities was $3,138,457 and $4,161,424 for the three months ended March 31, 2026, and 2025, respectively, a decrease of $1,022,967, or 25%. This decrease was primarily due to (i) an increase in R&D materials and accounts payable associated with operating activities, and (ii) differences in the timing associated with the payment of certain operating activities between the three months ended March 31, 2026, and 2025.

*Cash provided by investing activities*

We had no net cash provided by or used in investing activities for the three months ended March 31, 2026, and 2025.

*Cash provided by financing activities*

Net cash provided by financing activities was $13,356,857 and $6,028,102 during the three months ended March 31, 2026, and 2025, respectively. This increase of $7,328,755 was primarily due to differences in amounts raised by sales of our securities in capital raising activities conducted during the three months ended March 31, 2026, and 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 28

------

[**Table of Contents**](#toc)

**Item 3. Quantitative and Qualitative Disclosures About Market Risk**

The Company is not required to provide the information called for by this Item as it is a "smaller reporting company," as defined in Rule 12b-2 of the Exchange Act.

**Item 4. Controls and Procedures**

**Evaluation of Disclosure Controls and Procedures**

As required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act, our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2026. The term "disclosure controls and procedures" as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized, and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to a company's management, including its principal executive and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of March 31, 2026, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were not effective due to material weaknesses in our internal control over financial reporting related to a lack of segregation of duties between accounting and other functions and the absence of sufficient depth of in-house accounting personnel with the ability to properly account for complex transactions.

Due to our size and nature, segregation of all conflicting duties may not always be possible and may not be economically feasible. However, to the extent possible, the initiation of transactions, the custody of assets and the recording of transactions should be performed by separate individuals. Our size and nature also do not allow for our accounting staff to have depth of expertise in all areas that might be desirable, such as expertise in accounting for a variety of complex transactions. Management evaluated the impact of our failure to maintain effective segregation of duties and sufficient depth of personnel on our assessment of our internal control over financial reporting and has concluded that these control deficiencies represent material weaknesses.

In response to the material weaknesses described above, during the quarter ended March 31, 2026, we performed additional analysis and other post-closing procedures to ensure our financial statements were prepared in accordance with US GAAP. Accordingly, we believe that the financial statements included in this report fairly present, in all material respects, our financial condition, results of operations and cash flows for the periods presented.

**Remediation Plans**

Management is actively engaged in remediation efforts to address the material weaknesses identified in management's evaluation of internal controls and procedures. The remediation efforts, which have been or are in the process of being implemented, are intended to address the identified material weaknesses, and include:

• new accounting software, processes, and workflows to further segregate duties among limited accounting staff;

• specific review procedures, including the added involvement of our legal department to review certain accounting transactions following a given period in an effort to enhance accuracy of reporting;

• specific review procedures, including the added involvement of our manufacturing staff to enhance controls associated with the tracking and reporting of inventory values in our supply chain; 

• a formal Disclosure Committee that has oversight responsibility for the accuracy and timeliness of disclosures made by the Company through controls and procedures and the monitoring of their integrity and effectiveness; 

• additional hiring of staff and development of accounting processes and policies to further segregate accounting responsibilities and increase the depth of our expertise in accounting for a variety of complex transactions; and 

• additional training, testing, and certification of key accounting, finance, IT, and legal team members.

During the quarter ended March 31, 2026, we took actions to remediate the material weaknesses relating to our internal controls over financial reporting including: (i) continued evaluation and documentation of policies, processes, and controls, both manual and automated; (ii) identification and implementation of improvements to information technology and security controls and supporting control documentation; and (iii) evaluation of and updates to software workflows to further segregate duties, enhance accuracy of vendor billing, and ensure transparency and oversight from vendor or project managers, department leaders, legal team members, and finance team members.

As management continues to evaluate and work to improve its internal control over financial reporting, we may take additional measures to address control deficiencies, or we may modify certain of the remediation measures described above. While remediation efforts are active, management requires additional time to demonstrate the operating effectiveness of our remediation efforts. The material weaknesses cannot be considered remediated until the applicable remedial controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.

**Changes in Internal Control over Financial Reporting**

Except as described above, there were no changes in our internal control over financial reporting during the quarter ended March 31, 2026, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

**Inherent Limitations of Disclosure Controls and Internal Control over Financial Reporting**

Because of their inherent limitations, our disclosure controls and procedures and our internal control over financial reporting may not prevent material errors or fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. The effectiveness of our disclosure controls and procedures and our internal control over financial reporting is subject to risks, including that the controls may become inadequate because of changes in conditions or that the degree of compliance with our policies or procedures may deteriorate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 29

------

[**Table of Contents**](#toc)

**PART II – OTHER INFORMATION**

**Item 1. Legal Proceedings**

From time to time, we may be involved in legal proceedings that arise during the ordinary course of business. Although the results of legal proceedings cannot be predicted with certainty, we do not currently have any pending litigation to which we are a party or to which our property is subject that we believe to be material. Regardless of the outcome, litigation can be costly and time consuming, and it can divert management's attention from important business matters and initiatives, negatively impacting our overall operations.

**Item 1A. Risk Factors** 

The Company is not required to provide the information called for by this Item as it is a "smaller reporting company," as defined in Rule 12b-2 of the Exchange Act.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

During the three months ended March 31, 2026, we issued and sold the following unregistered securities:

On January 2, 2026, we issued 5,000 shares of our common stock to the Chairman of our Scientific Advisory Board in consideration for services during the three months ended March 31, 2026.<br>

The foregoing issuance of securities was not registered under the Securities Act or the securities laws of any state, and the securities were offered and issued in reliance on the exemption from registration under the Securities Act afforded by Section 4(a)(2).

**Item 3. Defaults Upon Senior Securities**

None.

**Item 4. Mine Safety Disclosures**

Not applicable.

**Item *5.* Other Information**

*<u>Rule</u> <u>*10b5*-*1*</u> <u>Trading Arrangements and Non-Rule</u> <u>*10b5*-*1*</u> <u>Trading Arrangements</u>*

During the fiscal quarter ended *March 31, 2026*, none of our officers or directors, as those terms are defined in Rule *16a*-*1*(f), adopted or terminated a "Rule *10b5*-*1* trading arrangement" or a "non-Rule *10b5*-*1* trading arrangement," as those terms are defined in Item *408* of Regulation S-K.

**Item 6. Exhibits**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 30

------

[**Table of Contents**](#toc)

**INDEX TO EXHIBITS**

---

| | |
|:---|:---|
| **Exhibit**<br> **Number** | **Description of Exhibit** |
| 3.1 | [Amended and Restated Certificate of Incorporation of the Registrant, dated April 3, 2018, incorporated by reference to Exhibit 3.1 of the Registrant's Current Report on Form 8-K filed on April 10, 2018.](http://www.sec.gov/Archives/edgar/data/1595248/000118518518000666/ex3-1.htm) |
| 3.2 | [Certificate of Amendment of the Amended and Restated Certificate of Incorporation, dated January 31, 2024, incorporated by reference to Exhibit 3.1 of the Registrant's Current Report on Form 8-K filed on January 31, 2024.](http://www.sec.gov/Archives/edgar/data/1595248/000143774924002620/ex_618362.htm) |
| 3.3 | [Certificate of Amendment of the Amended and Restated Certificate of Incorporation, dated October 16, 2025, incorporated by reference to Exhibit 3.1 of the Registrant's Current Report on Form 8-K filed on October 17, 2025.](http://www.sec.gov/Archives/edgar/data/1595248/000143774925031210/ex_865723.htm) |
| 3.4 | [Amended and Restated Bylaws of the Registrant, dated April 3, 2018, incorporated by reference to Exhibit 3.2 of the Registrant's Current Report on Form 8-K filed on April 10, 2018.](http://www.sec.gov/Archives/edgar/data/1595248/000118518518000666/ex3-2.htm) |
| 3.5 | [Amendment No. 1 adopted and approved by the Registrant's Board of Directors on October 18, 2023, incorporated by reference to Exhibit 3.1 of the Registrant's Current Report on Form 8-K filed on October 23, 2023.](http://www.sec.gov/Archives/edgar/data/1595248/000143774923028769/ex_582314.htm) |
| 3.6 | [Amendment No. 2 adopted and approved by Registrant's Board of Directors on March 29, 2025, incorporated by reference to Exhibit 3.5 of the Registrant's Annual Report on Form 10-K filed on April 1, 2025.](http://www.sec.gov/Archives/edgar/data/1595248/000143774925010311/ex_788396.htm) |
| 10.1+ | [Genprex, Inc. Amended and Restated Outside Director Compensation Policy, adopted March 9, 2026, incorporated by reference to Exhibit 10.5 of the Registrant's Annual Report on Form 10-K filed on March 30, 2026.](http://www.sec.gov/Archives/edgar/data/1595248/000143774926010346/ex_931485.htm) |
| 31.1\* | [Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ex_909578.htm) |
| 31.2\* | [Certification of Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ex_909579.htm) |
| 32.1\*\* | [Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ex_909580.htm) |
| 101.INS\* | Inline XBRL Instance Document. |
| 101.SCH\* | Inline XBRL Taxonomy Extension Schema Document. |
| 101.CAL\* | Inline XBRL Taxonomy Extension Calculation Linkbase Document. |
| 101.DEF\* | Inline XBRL Taxonomy Extension Definition Linkbase Document. |
| 101.LAB\* | Inline XBRL Taxonomy Extension Label Linkbase Document. |
| 101.PRE\* | Inline XBRL Taxonomy Extension Presentation Linkbase Document. |
| 104\* | Cover Page Interactive Data File (Formatted as Inline XBRL and contained in Exhibit 101). |

---

\* Filed herewith.

\*\* Furnished herewith.

+ Indicates management contract or compensatory plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 31

------

[**Table of Contents**](#toc)

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **GENPREX, INC.** | **GENPREX, INC.** |
|  | (Registrant) | (Registrant) |
| Date: May 13, 2026 | By: | /s/ Ryan M. Confer |
|  |  | Ryan M. Confer |
|  |  | Chief Executive Officer and Chief Financial Officer |
|  |  | (Principal Executive Officer and Principal Financial and Accounting Officer) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 32

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER OF GENPREX, INC. PURSUANT TO**

**RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Ryan M. Confer, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this quarterly report on Form 10-Q of Genprex, Inc., a Delaware corporation (the "registrant");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: May 13, 2026 | By:  | /s/ Ryan M. Confer |
|  |  | Ryan M. Confer |
|  |  | Chief Executive Officer  |
|  |  | (Principal Executive Officer) |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION OF CHIEF FINANCIAL OFFICER OF GENPREX, INC. PURSUANT TO**

**RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Ryan M. Confer, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this quarterly report on Form 10-Q of Genprex, Inc., a Delaware corporation (the "registrant");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: May 13, 2026 | By: | /s/ Ryan M. Confer |
|  |  | Ryan M. Confer<br> Chief Financial Officer<br> (Principal Financial and Accounting Officer) |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATIONS OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of Genprex, Inc. (the "Company") for the quarter ended March 31, 2026 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Ryan M. Confer, Chief Executive Officer and Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: May 13, 2026 | By:  | /s/ Ryan M. Confer |
|  |  | Ryan M. Confer |
|  |  | Chief Executive Officer and Chief Financial Officer |
|  |  | (Principal Executive Officer and Principal Financial and Accounting Officer) |

---

This certification accompanies the Report, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.